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Abstract Aptamers are single-stranded DNA or RNA
oligonucleotides, which are able to bind with high
affinity and specificity to their target. This property is
used for a multitude of applications, for instance as
molecular recognition elements in biosensors and other
assays. Biosensor application of aptamers offers the
possibility for fast and easy detection of environmental
relevant substances. Pharmaceutical residues, deriving
from human or animal medical treatment, are found in
surface, ground, and drinking water. At least the whole
range of frequently administered drugs can be detected
in noticeable concentrations. Biosensors and assays
based on aptamers as specific recognition elements are
very convenient for this application because aptamer
development is possible for toxic targets. Commonly
used biological receptors for biosensors like enzymes or
antibodies are mostly unavailable for the detection of
pharmaceuticals. This review describes the research
activities of aptamer and sensor developments for
pharmaceutical detection, with focus on environmental
applications.
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Introduction
Aptamers
Even though, until now, aptamers have been developed
mainly for medical applications or clinical diagnostics, they
are well suited as novel biological recognition elements for
the detection of pharmaceutical residues in the environment
because of their specific properties. Aptamers are short
single-stranded oligomers (ssDNA or RNA), which are
able to bind their target molecules with high specificity
and selectivity. Binding occurs because of their specific
and complex three-dimensional shape characterized by
stems, loops, bulges, hairpins, pseudoknots, triplexes, or
quadruplexes. The aptamer-target binding results from
structure compatibility, stacking of aromatic rings, elec-
trostatic and van der Waals interactions, and hydrogen
bondings, or from a combination of these effects [1, 2].
Initially, RNA aptamer development was described for
bacteriophage T4 DNA polymerase [3] and organic dyes
Cibacron blue and Reactive blue 4 [4]. These publications
described for the first time the evolutionary process to
select aptamers starting with of a big variety of oligonu-
cleotides in a so-called library (ca. 10
15 different structures)
by repeated rounds consisting of the steps (a) binding
between target molecule and library, (b) elution of the
bound oligonucleotides, and (c) their amplification. The
resulting pool of pre-selected oligonucleotides forms the
starting pool of the following round. This process is called
systematic evolution of ligands by exponential enrichment
(SELEX) and mimicks the Darwinian principle. The first
DNA aptamers were described only 2 years later for
Cibacron blue, Reactive blue 4, and Reactive green 19 [5].
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molecule classes and sizes were developed. Proteins are the
predominant aptamer selection targets, but aptamers are also
described for larger targets like whole cells, viruses, and
tissues, or smaller targets like small organic molecules [6].
The SELEX principle was modified with a lot of variations,
and most of them have their own names. The process of
aptamer selection with its variants is not in the focus of this
review. To get an overview, the reader is referred to our
former review article [2] and similar articles [7–10].
One of the biggest advantages of aptamers in comparison
to other biological recognition elements is the possibility to
develop them for toxic substances as the frequently used
biological recognition elements enzymes and antibodies
cannot be developed for toxic targets. Pharmaceuticals are
shown to have poisonous effects at least when used in high
doses. Therefore, the development of antibodies for pharma-
ceuticals is a difficult thing to deal with. Aptamers are
described for a great variety of pharmaceuticals with medical
application. Some of them are used in detection systems but
aremostlyutilizedforthemeasurementinbloodorotherbody
fluids. A new application field for aptamers is the detection of
pharmaceutical residues in the environment, which have to be
determined in a fast and simple way. On the other hand,
aptamers can be pharmaceuticals by themselves. These
aptamer therapeutics are used because of the high affinities
to their target and specificities comparable to those of
monoclonal antibodies for therapeutical treatments [11]. The
most successful therapeutic application of an aptamer has
been the adaptation of an antivascular endothelial growth
factor aptamer [12]. The PEGylated form of this aptamer
(called pegaptanib) is used as the medicinal active compo-
nent in a drug for treatment of age-related wet macular
degeneration. The pharmaceutical product Macugen®
(pegaptanib sodium injection) from Pfizer Inc./OSI Pharma-
ceuticals was approved in December 2004 (USA) and
January 2006 (Europe) [11, 13–15]. Aptamer therapeutics
will not be reviewed in this paper. The focus of our
examination lies on aptamers able to bind to pharmaceut-
icals, which are used for human and animal treatment and
can be found in surface and ground waters as well as in
drinking water. Pesticides are another group of water
pollutants, identified as an environmental problem much
earlier than pharmaceuticals. They are not considered in this
review.
Pharmaceuticals in the environment
Pharmaceuticals belong to the trace contaminants in water
which are large in number, low in quantity, huge in
interference, and high in toxicity and presenting high
challenges for detection on site and in real time [16]. The
enormous amount of about 95% of the pharmaceuticals
administered to humans is excreted unchanged or as
decomposition or conversion product in urine or stool.
Additionally, the disposal of leftover pharmaceuticals via
toilet or sink is still going strong. By this way, human
pharmaceuticals reach the wastewater treatment plants over
the path of the wastewater. Common wastewater filter
technologies do not remove all of the pharmaceutical
residues, which finally arrive at the surface water bodies.
A total of 95% of the pharmaceuticals found in the
environment derive from the treatment of humans and 5%
of animals [17]. The pharmaceuticals for animal treatment
often go directly to the soil with the urine of grazing
animals or by fertilization using stall manure and liquid
manure and drain away into the ground water or by surface
runoff into conterminous water bodies.
Although the pharmaceutical residues in the water
cycle are mostly in the range of nanograms or micro-
grams per liter, the implications of this presence are
mainly unknown. Anyhow, aquatic plants and animals
are exposed to the pharmaceutical residues during their
whole life time. Endocrine-disrupting substances in
lakes and rivers, for instance, lead to feminization of
male fish [18].
Drinking water is often made from ground and surface
water (in Germany 76.2% ground water, 13.3% surface
water, 10.5% others like bank filtrate) [19]. In this way,
pharmaceutical residues are directly imbibed by humans but
also enter the food and beverage industry. The entry of
antibiotics into the environment can lead to antibiotic
resistances. Infections of humans and animals with resistant
bacteria are life-threatening because they can no longer be
treated with antibiotics. Although the concentration of most
pharmaceuticals in drinking water is below therapeutic
doses and below the threshold values, the consequences to
human health of a permanent uptake of pharmaceuticals in
smallest amounts are still not investigated [20].
Aptamer-based systems for measurement, enrichment,
and elimination of pharmaceuticals
Aptamers can act as specific affinity binders to target
molecules. Their application is comparable to antibodies.
Aptamers developed for pharmaceuticals can be used as
biological receptors in assays, test systems, or biosensors
for the measurement of these pharmaceuticals in solutions
[21]. Moreover, they can be used for the enrichment of the
targetsubstances,especiallybeforemeasurementsinsolutions
with very low concentrations. Filtration and elimination of
target substances out of a water matrix is possible by the
application of aptamers [22].
The fast and easy detection of pharmaceutical residues
may help to differentiate between unpolluted and polluted
water regarding surface, ground, and drinking water.
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for:
– Automatic monitoring of the functionality of waste-
water treatment plants regarding pharmaceutical
degradation
– Analysis of immission pathways of pharmaceuticals
into the environment
– Construction of components of wastewater treatment
plants, like filters, to test the filtration effect using
markers
– Inspection of incoming components, like the raw
material “water” (production water as well as drinking
water) in the food production
Very important for all these aptamer applications are their
special properties such as reversible binding and reversible
folding which enables regeneration of the aptamer-target
binding.
Until now, standard methods for the determination of
pharmaceuticals are based mainly on methods like high-
performance liquid chromatography, gas chromatography
(GC), GC coupled with mass spectroscopy, or liquid
chromatography coupled with mass spectroscopy. All these
methods are laborious, time-consuming, and need highly
skilled personnel. Aptamer-based systems for pharmaceut-
icals detection would offer an alternative for fast and easy
detection of the substances. Moreover, when the aptamers
are coupled with very easy detection systems (for instance
colorimetric assays), an in-field screening of the relevant
substance in environmental samples would be possible.
Below, recent developments of RNA aptamers and their
properties are presented.
RNA aptamers for pharmaceuticals
Most of the investigations on RNA–drug interactions are
dedicated to antibiotics. Emerging bacterial resistances for
existing antibiotics pose a constant threat to human health.
In order to develop new drugs by a rational approach, it is
necessary to gain detailed knowledge of the mode of action
of existing antibiotics. Numerous antibiotics are known to
interact with different functional RNA species like rRNA
[23, 24], self-splicing introns [25], and hammerhead
ribozymes [26]. These interactions obstruct the normal
function of the respective RNA and associated molecules.
However, a detailed understanding of the underlying
principles that govern the molecular recognition between
antibiotics and RNA is lacking. Characterization of the full
length of naturally occurring RNA is rather tedious or even
unfeasible. So small binding RNA aptamers that are more
amenable to structural characterization are used as an
elegant alternative. These studies contribute plenty of
information on how different RNAs are able to bind to
small molecules. In contrast to antibiotics, the interactions
between RNA and other classes of molecules such as
psychotropics are only infrequently examined. Although
modifications that render RNA aptamers more stable to
environmental conditions can be easily introduced, the
application as molecular recognition elements is more an
exception than the rule. This field of application is
relinquished to the more suited DNA aptamers.
RNA aptamers for aminoglycoside antibiotics
Tobramycin
In order to investigate small RNA structures that are able to
recognize aminoglycosides, RNA capable of binding to
tobramycin was identified using an in vitro SELEX
approach [27]. After six cycles of selection, 18 clones were
sequenced. All of the clones were unique showing no
obvious consensus sequence. Clone W13 bound to a single
tobramycin molecule with a dissociation constant of
3.0 μM. The pool from the sixth round was subjected to
additional seven selection cycles. From the new pool, two
classes of consensus sequences with substantial sequence
homology were obtained. From each class, one representa-
tive (X1 and J6) was chosen for further study. Both
sequences displayed an additional high affinity binding site
resulting in a 2:1 stoichiometry between tobramycin and the
aptamers. The KD values for the binding to the high affinity
sites were 2 nM for J6 and 3 nM for X1, respectively,
whereas the corresponding KD values for the low affinity
sites were 6 μM for J6 and 16 μM for X1. The consensus
sequences were predicted to form stem-loop structures
which in turn were expected to constitute the binding
regions. Minimal structures truncated to the stem-loop
motifs (X1sl and J6sl) confirmed a 2:1 binding stoichiometry.
The high affinity binding sites were shown to have slightly
reduced affinities for tobramycin compared to the originally
selected aptamers.
In a subsequent study X1, J6 and an additional X3
sequence were characterized in more detail [28]. The
predicted stem-loop structures were confirmed to be the
tobramycin binding regions. Competition experiments with
neomycin, gentamicin, and erythromycin revealed affinities
that were three to six orders of magnitude lower for these
molecules than for tobramycin. NMR solution structures of
related versions of the selected aptamers confirmed the
stem-loop structures as the tobramycin binding sites and
provided a detailed picture of the specifics of the binding
[29, 30].
A simplified 39-mer version of J6 termed J6e with a
dissociation constant of 58 nM discriminated between
similar aminoglycosides as well [31]. A trinucleotide bulge
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binding. Substitutions that resulted in a shortening of the
loop were not tolerated.
Investigation of yet another J6-related sequence (J6f1)
showed that tobramycin is recognized by the bases of the
aptamer and does not interact with the phosphate backbone
[32]. The trinucleotide bulge is not directly involved in the
recognition of tobramycin but is necessary to pry open the
double helical region in order to allow tobramycin to access
the bases of the aptamer.
Aptamers for tobramycin that could be converted into
beacon aptamers were selected using a selection process
designed to obtain sequences that undergo a conformational
change upon the binding of tobramycin [33]. Two sequence
families were obtained after 14 selection cycles. These
sequences were unrelated to the previously selected
aptamers [27]. One clone from each family was converted
into a beacon aptamer (BA14-1 and BA14-2). Increase in
fluorescence intensity upon tobramycin binding was found
to be modest but reproducible. KD values were approxi-
mately 16 μM for BA14-2 and 500 μM for BA14-1.
Paromomycin was shown to exhibit no response.
A new selection cycle using a partially randomized
version of the previously selected BA14-2 aptamer [33]a sa
starting point was carried out by Vandenengel and Morse
[34]. A mutational variant of BA14-2 termed A415256
showed a five times lower minimal detection limit (2 μM)
for tobramycin compared to the original BA14-2 (10 μM).
The detection limit for kanamycin B was determined to be
30 μM but with a significantly decreased efficiency.
Kanamycin A was barely detectable at 30 μM whereas
amikacin and paromomycin showed no response.
Neomycin B
Neomycin B binds to different RNA targets including 16S
rRNA, the group I intron, and the hammerhead ribozyme.
One possible explanation for this behavior is that these
RNA structures share a common structural motif.
In order to identify structural requirements for neomycin
B binding, small RNA sequences suited for neomycin B
binding were isolated by in vitro selection [35]. Eight
rounds of selection resulted in 21 aptamer clones which
shared a 13-nucleotide consensus sequence in approximate-
ly half of the cases. The conserved region folded into a
stem-loop structure. The loop consisted of a five base
consensus sequence whereas the stems varied in sequence
and in length. However, sequences that did not share the
consensus sequence folded into stem-loop structures as
well. The overall stem-loop structure could be confirmed to
provide the neomycin B binding site. The KD value for the
clone neo5 was determined to be 115 nM. The related
paromomycin bound with a 100 times lower affinity.
Binding of the aptamer to neomycin B was found to be
Mg
2+ dependent. Based on the facts that neomycin B was
recognized by different selected RNA molecules with
variations in the consensus sequence and that no consensus
sequence was found compared to natural occurring RNA,
the authors concluded that the molecular three-dimensional
shape of the RNA molecules is the crucial factor for
neomycin B binding rather than a specific RNA sequence.
Details of the molecular recognition between the
aptamers and neomycin B were investigated by other
research groups. The NMR structure of a complex between
a 23-mer version of the selected aptamers and neomycin B
revealed that the rings I and II of the neomycin B molecule
are anchored within a RNA binding pocket [36]. Binding of
neomycin to this pocket is governed by hydrogen bonding
[37]. The directional characteristics of hydrogen bonds
provide an explanation of the observed variations in
affinities of aptamers for aminoglycosides that differ
slightly in stereochemistry and in the position of their
functional groups. Two additional low affinity binding sites
could be discovered using spectroscopic methods [38].
These sites are nonspecific and result from electrostatic
interactions between the RNA backbone and the neomycin
molecule.
An additional selection using a different selection
scheme was successfully carried out providing further
insights into sequence requirements for neomycin B
binding [39]. Five rounds of selection using a pool
including a 47-nucleotide sequence from the 16S rRNA
with 30% degeneracy per position were successful in
yielding binding sequences for neomycin B. The selected
sequences were no longer able to fold into the wild-type
secondary structure (motif A). Sequences corresponding to
the consensus sequence folded into the same hairpin motif
(motif B) as the previously selected aptamers that were
obtained using a completely randomized library [35]. The
dissociation constant for a motif B aptamer (clone22) was
determined to be 0.5 μM. Motif A sequences were shown
to have lower affinities. The selection showed that
optimized sequences for neomycin B that bind with higher
affinities compared to natural occurring RNA can be readily
obtained by in vitro selection.
Kanamycin A
An evolutionary relationship between naturally occurring
functional RNA molecules would provide an explanation
for the observed interactions of aminoglycoside antibiotics
with diverse functional RNA. In order to estimate the
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aminoglycoside antibiotic kanamycin A (and lividomycin,
see below), an in vitro selection was performed by Lato et
al. [40]. Four selection cycles resulted in an RNA pool that
was estimated to contain approximately 10
6 different
sequences for kanamycin A binding. Because of this great
number, only a spot check of individual sequences was
possible. No duplications and obvious sequence motifs
could be recognized. Secondary structure predictions
revealed a multitude of single and multiple stem-loops,
internal loops, multiarm junctions, and stems with or
without bulges. A predominant motif was not observed.
Affinity elution was used to determine binding constants
which were estimated to be no more than 220 nM.
Specificity tests showed that members of the kanamycin
family (dibekacin and amikacin) bind tighter to the selected
RNA than the less similar ribostamycin or the unrelated
streptomycin. Although kanamycin A and kanamycin B
differ only by one amino group, some of the selected
sequences were able to distinguish between these mole-
cules. Comparison to aminoglycoside binding sites on
naturally occurring RNA species exhibited no structural
similarities despite of the functional similarities. The
authors concluded from the fact that there is a multitude
of structures for kanamycin A binding that different
unrelated RNA species could have evolved to bind to
aminoglycosides, and therefore, a single RNA ancestor for
today’s functional RNA molecules is rather unlikely. This
conclusion seems to be open for discussion. Four rounds of
selection may not be sufficient to effectively narrow down
the pool to the best binding sequences. A small subset of
high affinity binders may be hidden in the highly divergent
pool and is most likely to be missing in the characterization
procedures. Therefore, potential similarities to natural
occurring RNA structures are very likely to escape the
notice of the authors.
Kanamycin B
To gain insight into the general rules that govern the
recognition between RNA and different aminoglycoside
antibiotics, kanamycin B was chosen as a target for in vitro
selection [41]. Kanamycin B was considered to be a
promising target because it differs only by an additional
hydroxyl group from tobramycin for which tightly binding
aptamers were already selected [27]. Twelve clones from
the ninth selection cycle were investigated. Three sequen-
ces were found to be identical, but no further sequence
homology with the remaining sequences was discovered.
The triplicated RNA (K8) was the best binding sequence
with a KD of 180 nM. K8 was able to discriminate between
kanamycin B and paromomycin by a factor of approxi-
mately 10. The dissociation constant for kanamycin A was
4.4 μM suggesting an important role for the 2-amino group
in the A-ring of kanamycin B for the target recognition.
Tobramycin was found to bind even tighter to K8 (KD=
11.6 nM) compared to the actual selection target kanamycin
B. Secondary structure prediction of K8 revealed a
molecule composed of stem-loop structures containing
several bulges. A 22-nucleotide minimal version was
predicted to form a short stem with a bulge and a loop at
the 5′-end of the aptamer. A non-canonical base pair was
suggested to lead to a widening of the groove that hosts the
aminoglycoside. The identities of the bases in the loop were
found to be essential for aminoglycoside binding.
Lividomycin
In the same study that was performed to select aptamers for
kanamycin A (see above), lividomycin was an alternative
target to explore if different functional RNA species are
descendants of a common ancestor [40]. Four selection
cycles revealed a large variety of binding sequences
without any recognizable conserved sequences or second-
ary structure motifs. Six binding sequences were chosen for
further investigation. Specificity was evaluated using
related and unrelated aminoglycoside antibiotics. Members
from the same family like neomycin and paromomycin
were found to bind more tightly to the selected sequences
than less similar molecules such as ribostamycin and
kanamycin. KD values of individual aptamers were found
to be 300 nM on average or less. The authors’ conclusion
that the obtained results suggest a multitude of different
binding motifs for aminoglycoside antibiotics suffers from
the same drawback mentioned in the kanamycin A
paragraph. Four selection rounds are most likely inadequate
to identify the best binding motifs so the conclusions drawn
from the highly divergent fourth round pool may be
inaccurate.
Another attempt including additional rounds of selection
was performed to discover potential binding sites in
naturally occurring RNA [42]. The selection was conducted
in analogy to the original one [40], but six additional
rounds with increased stringency were performed. In
contrast to the previous selection, 12 of the 13 clones
investigated were found to be identical. A stem-loop
structure was predicted for the dominant species. Elements
of the constant 3′-region are involved in forming a long
stem structure. Regrettably no truncation experiments were
carried out, so it remains unclear if the invariable primer
region is necessary for target binding. Comparison of the
obtained sequence with genomic data revealed that the
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As apparent from this selection, the strategy to search for
new potential targets for existing drugs rather than search-
ing for new drugs seems to be a promising approach.
Streptomycin
Streptomycin interacts with ribosomal RNA and thereby
interferes with translation. Inhibition of the self-splicing of
group I intron RNA is also known. RNA sequences capable
of binding streptomycin were selected to address the basic
question how RNA molecules are able to bind to their
respective ligand [43]. Four rounds of selection were
performed before splitting the obtained pool. One part of
the pool was subjected to three additional cycles. The other
part was subjected to a counterselection step against
bluensomycin followed by three cycles without counter-
selection. From the counterselection procedure, a 22-
nucleotide sequence (motif 1) without sequence variations
was obtained. The procedure without any counterselection
steps resulted in a 26-nucleotide sequence (motif 2) with
sequence variations in only two bases. Three sequences that
differed from motif 1 and motif 2 bound to streptomycin
and suggested the formation of alternative binding motifs
for the antibiotic. Minimal binding sequences for motif 1
and motif 2 consisted of 46 and 41 bases, respectively. The
motif 1 minimer showed a strong discrimination between
streptomycin and bluensomycin. This indicates that the
single counterselection step was effective. The motif 2
minimer showed a lower affinity for streptomycin com-
pared to the motif 1 minimer and bound to both antibiotics
but had a preference for streptomycin. Mg
2+ was shown to
be an essential cofactor because no binding with either
motif was detected in the absence of the ion. Conforma-
tional changes upon ligand binding in the presence of Mg
2+
were observed for motif 1 but not for motif 2. Secondary
structure prediction revealed two asymmetric internal loops
separated by a stem. The structure is capped by a hairpin
loop. No similarities to natural binding sites were found.
The X-ray structure of the binding complex showed that
streptomycin is inserted in a pocket that includes elements
from both asymmetric loops [44]. A total of three cation
binding sites were suggested to stabilize an unusual
conformation of the 5′-site.
RNA aptamers for tetracycline antibiotics
Doxycycline
Aptamers for the antibiotic doxycycline were selected
exploiting the allosteric inhibition of a hammerhead
ribozyme fused to a randomized RNA library [45]. Clones
from cycles 10, 13, and 16 were sequenced. Eight different
sequence classes were identified. After the cycles 10 and
13, an error-prone PCR step was introduced in order to
increase the complexity of the enriched pool. The inhibition
values Ki for the four clones that showed the best inhibition
is in the range of 20 to 70 nM. Specificity of the selected
sequences was tested using tetracycline which differs only
by one hydroxyl group from the original target doxycy-
cline. Two clones showed an at least 10,000-fold discrim-
ination between the two related substances. The two
remaining clones exhibited a slightly enhanced discrimina-
tion of four to five times. The authors suggested the
formation of a different binding pocket for these low
discrimination sequences. The clone with the highest
affinity (16–05) but with only modest discrimination
abilities was subjected to further investigation in order to
identify the minimal binding motif. A truncated sequence
consisting exclusively of the randomized region was not
sufficient for the binding to doxycycline. A helix domain of
the fused hammerhead substructure was found to be a
necessary component for the correct recognition of the
target.
Tetracycline
Tetracycline interferes with the binding of the aminoacetyl-
tRNA to the ribosomal A-site at the 30S ribosomal subunit
and therefore inhibits the bacterial protein synthesis.
Because the details of this interaction were poorly under-
stood, a selection was performed with the aim to obtain
aptamers against tetracycline with an affinity comparable to
that of the small ribosomal subunit [46]. Binding sequences
from round 13 and 14 were sequenced. The sequence cb28
was chosen for further analysis because its KD value of
1 μM was in the desired affinity range. The lead cleavage
pattern suggested that the aptamer changes conformation
upon ligand binding. In the absence of Mg
2+, no binding
was observed. Secondary structure prediction revealed an
arrangement of several stems and loops. Some of them
could be deleted without a loss of function. A minimal
version of cb28 consisting of 60 nucleotides was predicted
to form a stem-loop structure. Different tetracyclines were
usedtotestthespecificityoftheaptamer.ClassIItetracyclines
which do not efficiently inhibit bacterial translation bound
only poorly to cb28. Class I tetracyclines which inhibit
prokaryotic translation bound with good affinities with the
exception of doxycycline and minocycline. These findings
suggested that the hydroxyl group at position 6 in the
tetracycline molecule is a prerequisite for binding. A different
binding mechanism for the aptamer and the ribosome was
concluded. The authors suggested tetracycline binding to
interhelical regions and accommodation in a three-way
junction instead of the simple stem-loop motif usually
observed for aminoglycoside antibiotic binding sites. The
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for the tetracycline antibiotic doxycycline [45].
The X-ray cocrystal structure of the cb28 minimer
revealed the formation of a non-canonical pseudoknot
[47]. The structure was stabilized by tetracycline and
several tightly bound divalent cations. The antibiotic itself
bound to the RNA as a magnesium chelate. This form of
binding is known from tetracycline binding to the 30S
subunit of the bacterial ribosome as well. In comparison to
other small molecule aptamers, the proposed three-helix
junction is unique and similar to naturally occurring
riboswitches.
RNA aptamers for further antibiotics
Viomycin
Viomycin is a small cyclic peptide antibiotic that interferes
with prokaryotic protein synthesis as well as group I intron
self-splicing. A selection of RNA sequences that bind to
viomycin was conducted in order to investigate the
molecular basis of the recognition of viomycin by RNA
[48]. Seven rounds of selection resulted in 23 sequences.
Only one of these sequences was selected multiple times. A
stretch of 14 nucleotides showed a close relationship for
different clones at the primary sequence level. Bases at both
ends of this region were able to form base pairs.
Accordingly, a stem-loop structure was proposed. Dissoci-
ation constants for sequences containing this consensus
sequence were in the range of 11 to 21 μM. A truncated
version consisting only of the conserved loop and a six-
base stem was not sufficient for viomycin binding.
Additional investigations revealed that a shortage from the
3′-end of the aptamer was not tolerated. Bases located in
this region have the potential to base pair with the
conserved loop structure. This pairing results in the
formation of a pseudoknot structure. Natural target sites of
viomycin are proposed to fold into pseudoknot structures as
well [49]. The authors concluded that viomycin has
specificity for pseudoknot structures and is able to
recognize particular pseudoknots.
Linezolid
Linezolid is an oxazolidinone antibiotic that interferes with
bacterial protein synthesis by inhibition of the ribosomal
function. A linezolid–neomycin conjugate was successfully
used to select linezolid binding sequences from a genomic
library [50]. Eight rounds of selection were performed, and
three clones that were selected multiple times were chosen
for further investigation. Structure prediction revealed a
typical stem-loop motif. Dissociation constants of truncated
versions of the selected aptamers binding to the hetero-
conjugate were in the range of 66 to 260 nM. Neomycin
which is part of the heteroconjugate bound with an affinity of
about 300 nM. Due to the weak affinity of linezolid to the
selected sequences, a direct binding could not be observed.
Neomycin bound exclusively to the stem region. The binding
of the heteroconjugate was extended to the terminal loop, and
accordingly, this site was assigned to be the binding site for
linezolid. Surface plasmon resonance (SPR) measurements
using the strongest binding sequence (L2-12) resulted in an
affinityof5.4mMforlinezolid.Theaffinityinthepresenceof
neomycin was 0.45 mM which supported the assumption of
different binding sites for both molecules.
Chloramphenicol
Chloramphenicol inhibits the peptidyl transferase activity in
prokaryotes by association with the 23S rRNA which is
involved in the peptide bond formation. Recognition of
chloramphenicol by RNA was studied investigating RNA
molecules that are able to bind to the antibiotic [51]. Two
libraries differing in the length of the random region were
subjected to the selection procedure. After 12 rounds of
selection, 96 aptamer clones were investigated of which 74
were shown to be unique. KD values ranged from 200 μMt o
less than 2 μM. The best binding sequences were the best
represented sequences in the enriched pool. Nine sequences
were predicted to fold into helices containing two asymmetric
bulges formed by four to six adenosines located across a
single adenosine. A minimal 50-nucleotide version containing
both asymmetric bulges (Cam1) and a 33-nucleotide version
containing only one asymmetric bulge (Cam2) were prepared.
Cam1 had an affinity comparable to the full-length RNA
whereas Cam2 showed no activity. Five additional rounds of
selection using Cam1 with a 15% mutagenesis rate per
position were performed. Domains that were supposed to
form the binding sites such as the successive adenosines in
the bulges were found to be invariant or nearly invariant.
Reselection of a mutated version of Cam2 showed activity
after six rounds. No resemblance to the original Cam2
molecules was observed. The sequences seemed to have
diverged to other binding motifs that were not further
evaluated. NMR studies revealed a 1:1 stoichiometry between
Cam1 and chloramphenicol. This result is rather surprising
because chloramphenicol itself is not a symmetrical molecule.
One explanation is that both binding sites might not be
accessible at the same time. But the lack of activity of Cam2
contradicts this assumption. An alternative explanation is the
formation of tertiary interactions between both of the
adenosine elements that provide a single binding site. The
authors proposed this as a mechanism for the chloramphen-
icol binding in the 23S rRNA where the formation of a
similar structure would bring into contact three regions that
are thought to be involved in chloramphenicol binding.
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Moenomycins inhibit the bacterial cell wall synthesis by
interacting with the transglycosylase resulting in the
prevention of chain elongation of the formed polysaccha-
ride strand. One strategy to discover new drugs is to search
for biosynthetic precursors of already existing drugs. In the
next step, these precursors may be used to construct semi-
synthetic libraries which in turn are screened for active
compounds [52]. Because there are no classical antibodies
for derivatives of the antibiotic moenomycin A, a screening
for RNA sequences that are able to bind to moenomycin A
was performed [52]. A total of 12 selection cycles using
three slightly different approaches resulted in approximately
100 clones to be investigated. The selected RNA molecules
were dominated by two motifs. The invariable primer binding
sites were shown to be not necessary for binding. Dissociation
constantsweredeterminedtobeintherangeof300to400nM.
Unfortunately, secondary structures were not examined so
comparisontoothersmallmoleculebindingRNAmotifsisnot
possible. Competition assays demonstrated that the selected
aptamers recognize the disaccharide portion of moenomycin
A. Fluorescence correlation spectroscopy using a tetramethyl-
rhodamine derivative of moenomycin was applied to study the
formation of the RNA–moenomycin complex [53]. One
representative of the previously selected aptamers [52]( A 6 )
was shown to have a KD value of 437 nM. This value is in
good agreement with the 320 nM for the same aptamer
obtained using affinity chromatography.
RNA aptamers for pharmaceuticals with psychotropic
effects
Codeine
Codeineisaconstituentofopiumandwidelyusedasanarcotic
drug but is often abused for its euphoric and depressant effects
[54]. Possible applications of codeine binding aptamers in
sensor systems or as tools for biotechnological purposes
prompted Win et al. to select aptamers against codeine [55].
Fifteen selection cycles including three error-prone PCR steps
in rounds 11 to 13 and a counterselection step against
morphine yielded about 60 clones. Five identical sequences
and two sets with one-nucleotide difference were identified.
The remaining sequences were shown to be unique. A
consensus sequence or structural similarity between the
different sequences could not be observed, but short stretches
of identical bases were found in many clones. Sequences with
the highest affinities (FC5 and FC45) were chosen for further
analysis. KD values for binding in solution were 4.5 μMf o r
FC5 and 47 μM for FC45. A higher specificity for codeine
compared to morphine was reflected by lower affinities for
morphine (25 μM for FC5 and 212 μM for FC45). The
successful molecular discrimination is based on a single
methyl group by which codeine differs from morphine. FC5
showed a higher affinity for thebaine compared to codeine
whereas FC45 had a higher affinity for codeine. The authors
suggested that this behavior is a consequence of the
immobilization procedure which allowed no presentation of
differential functional groups. This in turn implies that the
selected aptamers are able to recognize conformational
differences between thebaine and codeine. A truncated 41-
nucleotide version of FC5 (FC5L) including the random
region and the 5′ constant region exhibited an affinity for
codeinecomparabletothe59-nucleotideparentsequence.The
analog 44 minimer of FC45 (FC45L) bound to codeine with
an almost identical affinity as the original aptamer. The
predicted structures of the minimal aptamers revealed stem-
loop structures which differed from other known stem-loop
structures in the length of the stem region which is composed
of only two to three base pairs. Modifications that extended
the stems were tolerated as demonstrated by comparable
affinities for codeine.
Theophylline
Theophylline is a naturally occurring alkaloid used in the
treatment of asthma and bronchitis [56]. A theophylline
aptamer was obtained by Jenison et al. after eight selection
cycles [57]. A simultaneous selection introduced a counter-
selection step against the related caffeine in round five. A
consensus secondary structural motif revealed a stem-loop
structure which encompasses the binding region. An RNA
sequence from the pool that was subjected to the counter-
selection against caffeine (TCT8-4) was chosen to determine
the binding characteristics. The affinity to theophylline was
determined to be 0.6 μM. No binding was detected in the
absence of magnesium ions. A truncated version containing
38nucleotides(mTCT8-4)wasusedtodetermine theminimal
binding requirements. This minimal version showed an
enhancedaffinityof0.1 μM.Caffeine and nineother xanthine
derivatives were chosen for competition experiments. The
affinities ranged from three times lower affinity for CP-
theophylline to a 10,000 times lower affinity for caffeine.
From these assays, the authors concluded that the N-7
hydrogen is essential for theophylline binding. NMR meas-
urements showed a conformational change upon ligand
binding and revealeda 1:1 stoichiometry between the selected
aptamer and theophylline.
Dopamine
Dopamine is a catecholamine neurotransmitter which is
supposed to play an essential role in degenerative disorders
of the central nervous system culminating in diseases like
schizophrenia [58], Huntington’sd i s e a s e[ 59], and Parkinson’s
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Mannironi et al. [61]. After nine rounds of selection, 44 clones
were sequenced and 20 of them were found to be identical.
No sequence homology between the different clones could be
observed so that various sequences of RNA that are able to
bind to dopamine seem to exist. The most abundant clone
d o p a 2w i t ha na f f i n i t yo f2 . 8μM was chosen for further
analysis. Secondary structure predictions showed an arrange-
ment of four stem-loop motifs. Truncation at the 3′-end
eliminating one stem-loop and parts of another stem were
tolerated without a loss of function. The 5′-end including the
invariable primer region was necessary for target binding.
This truncated version termed dopa2/c.1 showed an increased
affinity (1.6 μM) compared to the parent aptamer. Binding
experiments with various dopamine analogs indicated that the
aliphatic chain and the hydroxyl group at position 3 are
essential for the ligand-target recognition. Six additional
rounds using a pool of partially randomized versions of
dopa2 were performed. Sequence comparison between the
original and the reselected sequences hinted at tertiary
interactions between two of the loop structures. The binding
pocket was proposed to be formed by canonical or wobble
base pairing between the two loop structures. For the correct
folding of the aptamer, magnesium ions were found to be
essential. The minimal binding sequence had a length of 57
nucleotides which is relatively large compared to aptamers
selected for other small molecules. RNA sequences that are
able to bind to this neurotransmitter were successfully selected
although there are no known interactions between nucleic
acids and dopamine in vivo.
The described RNA aptamers are almost exclusively
used as tools for the unraveling of molecular recognition
processes occurring between functional RNA molecules
and antibiotics. The required structural information can be
more easily assessed for small RNA aptamers compared to
the large natural RNAs. Stem-loop structures seem espe-
cially suited for the accommodation of aminoglycoside
antibiotics. RNA aptamers for antibiotics that do not belong
to the aminoglycoside class exhibit alternative structural
motifs like pseudoknot structures (viomycin), asymmetric
bulges connected by a stem (chloramphenicol), or a three-
helix junction (doxycycline).
Furthermore, RNA aptamers can be successfully con-
verted into beacon aptamers which respond with enhanced
fluorescence intensity to the presence of the respective
target. Alternatively, RNA aptamers are used to determine
consensus sequences for the binding of the target in
question. Alignments with genetic data reveal potential
new target structures for already existing drugs. Utilization
as antibodies in order to search for precursors of existing
drugs which in turn can be screened for potential activity is
another promising field of application.
DNA aptamers for pharmaceuticals
The following chapter reviews articles on DNA aptamers
developed to detect pharmaceuticals. Since DNA aptamers
are appropriate for various purposes in different research
areas, examples described in this section include those
aimed at medical, biotechnological, or environmental
applications.
DNA aptamers for antibiotics
Anthracyclines
Anthracyclines are a class of antibiotics derived from
Streptomyces bacteria and frequently used as cytostatics in
chemotherapy to treat various kinds of cancers [62]. A high
percentage (∼37%) of these administrated anthracyclines is
excreted unmetabolized in urine [63]. If not degraded or
eliminated, they may accumulate in the environment and
possibly reach the drinking water or contaminate the soil.
Wochner et al. [64] selected and characterized DNA
aptamers with high affinity and specificity for the most
common anthracyclines daunomycin and its hydroxyl
derivate doxorubicin. The aptamer development was carried
out by a semiautomatic in vitro selection [65] by using
daunomycin as target, immobilized on magnetic beads.
After ten rounds of selection, a group of daunomycin-
binding aptamers with high-sequence similarity and a high
G-content was identified and characterized. Competition of
binding studies with fluorescent dye-linked aptamer assay
[66], enzyme-linked aptamer assay (ELAA), and surface
plasmon resonance assay (Biacore X) determined the best
binder and its specificity for daunomycin and doxorubicin.
KD values for daunomycin were 20 nM for the best binder
(clone 10.10) and 272 nM for the 41-mer truncated
sequence 10.10v. The truncation experiments exposed the
binding region as a G-rich domain with contiguous,
stabilizing sequence parts.
Tetracyclines
Tetracyclines are a class of broad spectrum antimicrobial
agents, which comprise various tetracycline nucleus derivates
differing only in the presence or absence of –Ha n d–OH
groups around the tetracycline backbone. Tetracyclines are
applied in human therapy, animal husbandry, aquafarming,
and fruit crop production. They are extensively used in
veterinary medicine and as growth promoters for animals.
Only a small percentage of the administered antibiotics is
metabolized in the animals. Accordingly, a large fraction is
either accumulated in tissues or excreted. Hence, tetracyclines
are found infoodproductslikemeat, milk, and eggs[67]o ri n
the environment [68].
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tetracyclines by a combination of the Toggle-SELEX [71]
and FluMag-SELEX [72] methods. Four rounds of FluMag-
SELEX with oxytetracycline immobilized on magnetic beads
were accomplished before carrying out a counter SELEX
with tetracycline. Each of the resulting fractions was
subjected to a separate SELEX procedure. In one of these
SELEX procedures [70], oxytetracycline beads were used,
and after eight rounds of selection and a subsequent counter
SELEX to doxycycline, five different types of sequences
were found. Four of these bound specifically to oxytetracy-
cline in a low nanomolar range (KD=9.61±0.3 nM for
aptamer no. 4, 12.08±2.25 nM for aptamer no. 5, 56.84±
3.62 nM for aptamer no. 20, and 121.1±5.3 nM for aptamer
no. 2; performed by equilibrium dialysis). Aptamer no.
20 was highly specific for oxytetracycline with no or
insignificant binding to tetracycline and doxycycline,
followed by no. 5 and 4. Aptamers no. 2 and 4 showed to
possess a binding capacity of about 3–5% with tetracycline
and doxycycline, but they also showed a considerably higher
binding preference to oxytetracycline. The best binders were
predicted to form G-quartet structures.
The other SELEX procedure [69] was carried out in two
phases: In the first part, four SELEX rounds with
oxytetracycline-modified beads were performed, with a tetra-
cycline counterselection. In the following part of selection,
tetracycline modified beads were used and a counterselection
with doxycycline was done. After 12 SELEX rounds (all in
all), 20 tetracycline group-specific aptamers were obtained
which bound more than one analog of tetracycline antibiotics.
Seven of these aptamers featured high affinities for the basic
tetracycline backbone. Affinity constants of the aptamers were
determined in the range of 63 to 483 nM (values see Table 1).
The palindromic sequence motif GGTGTGG or one of its
truncated forms seems to be essential for binding to the
tetracycline backbone, as one of them was present in all of the
aptamers, including those binding to oxytetracycline.
Kanamycins
Kanamycins are a group of structural closely related amino-
glycosidic antibiotics used to treat a broad variety of bacterial
infections, especially in veterinary medicine. Despite their
impressive clinical effectiveness, kanamycins are potentially
ototoxic and nephrotoxic in humans and animals. Thus,
monitoring the level of kanamycin residues in food or
drinking water is essential for the maintenance of public
health [73]. Commercially available kanamycin is a mixture
of kanamycins A, B, and C but contains mainly kanamycin
A( ∼75%). Another frequently used antibiotic of the kanamy-
cin group is tobramycin.
Recently, DNA aptamers for kanamycin were selected
by Song et al. [74]. The selection procedure was carried out
by affinity chromatography, in which commercially available
kanamycin was immobilized on cyanogen bromide-activated
sepharose beads. After nine rounds of in vitro selection and
amplification, six groups of aptamers with specificity for
kanamycin and its derivatives were enriched. The binding
aptamers had a high G-content, and the authors found a
consensus region composed of a stem-loop with a double G-
residueintheloopthatwasshowntobenecessaryforbinding.
Binding assays with fluorescence-labeled oligonucleotides
revealed affinity constants of 85.6 nM for aptamer Kana2 as
the aptamer with the strongest binding affinity to kanamycin
out of the six selected aptamer groups. A minimized 21-mer
from the Kana2 aptamer (called Ky2) containing the
conserved secondary structure showed an affinity constant of
78.8nMforkanamycin. Ky2alsoboundtobothkanamycin B
(KD=84.5 nM) and tobramycin (KD=103 nM). No binding
could be detected to streptomycin, sulfadimethoxine, and
ampicillin. The Ky2 aptamer has been applied in a gold
nanoparticle-based colorimetric, simple, and easy-to-handle
kanamycin assay, allowing detection of kanamycin at a level
as low as 25 nM.
DNA aptamers for pharmaceuticals with psychotropic
effects
Cocaine
Cocaine (benzoylmethylecgonine) is a crystalline tropane
alkaloid and a derivative of ecgonine. Cocaine acts as a
very strong stimulant of the central nervous system and as
an appetite suppressant. It is a popular illegal drug with
high addictive potential. Current studies pointed out the
problematical contamination of cocaine in surface and
waste waters in various countries [75–78].
Stojanovic et al. selected a cocaine-specific aptamer and
were the first to describe its application [79–81]. The aptamer
undergoes a formidable structure change while binding to
cocaine. Because of this feature, a multitude of researchers
applied this aptamer in various analytical systems [82–85].
However, there is no publication describing the actual
aptamer selection. The cocaine aptamer called MNS-4.1
seems to provide the initial aptamer structure with the
proposed cocaine binding pocket located in the center of a
three-way junction structure [80]. The dissociation constant
of this aptamer is given with ∼0.4 to 10 μM[ 80]. The
aptamer MNS-7.9 was constructed by shortening one of the
stems. It retained significant, albeit reduced affinity for
cocaine with KD∼20 μM[ 80]. Moreover, the aptamer MNS-
4.1 was separated at a predicted loop into two subunits C2-D
and F-C1 with KD∼200 μM[ 79]. Most of the multitude
aptamer-based cocaine biosensors and assays are based on
these aptamer structures. They are described in more detail in
the “Aptamer-based detection systems” section.
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Substance class Selection target Chemical structure - o g i l O
nucleotide
Name of 
aptamer 
KD value Ref 
Antibiotics
Aminoglycoside
antibiotics
Tobramycin RNA W13
J6
X1
J6e
BA 14-2
BA 14-1
3.0 µM
6µ M
16 µM
58 nM
16 µM
500 µM
[27]
[27]
[27]
[31]
[33]
[33]
Neomycin B RNA neo5
clone22
115 nM
0.5 µM
[35]
[39]
Kanamycin DNA Kana2
Ky2
Ky2
Ky2
85.6 nM
78.8 nM
84.5 nM for kanamycin B
103 nM for tobramycin
[74]
Kanamycin A  RNA <220 nM [40]
Kanamycin B RNA K8 180 nM
4.4 µM for kanamycin A
11.6 nM for tobramycin
[41]
Lividomycin RNA 300 nM [40]
Streptomycin ] 3 4 [ A N R
Tetracycline Tetracycline RNA
DNA
cb28
T7
T15
T19
T20
1µ M
357.8 nM
197 nM
424.8 nM
63.6 nM
[46]
[69]
T22
T23
T24
483.5 nM
100.6 nM
70.7 nM
Doxycycline ] 5 4 [ A N R
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No. 5
No. 20
No. 2
9.61±0 3 nM
12.08±2.25 nM
56.84±3.62 nM
121.1±5.3 nM
[70]
Anthracycline Daunomycin
(Daunorubicin)
DNA 10.10
10.10v
20 nM
272 nM
[64]
Further antibiotics Viomycin RNA 11–21µM [48]
Substance class  Selection target  Chemical structure - o g i l O
nucleotide
Name of 
aptamer 
KD value Ref 
Linezolid RNA
L2-12
66 – 260 nM for linezolid
neomycin heteroconjugate
300 nM for neomycin
5.4 mM
[50]
Chloramphenicol RNA 2 – 200 µM [51]
Moenomycin A RNA
(A6)
(A6)
300 – 400 nM
437 nM by FCS
320 nM by affinity
chromatography
[52]
[53]
Pharmaceuticals
with psychotropic
effects
Codeine RNA FC5
FC45
FC5
FC45
4.5 µM
47 µM
25 µM for morphine
212 µM
[55]
Theophylline RNA TCT8-4
mTCT8-4
0.6 µM
0.1 µM
[57]
Cocaine DNA
DNA
DNA
DNA
MNS-4.1
MNS-7.9
F7.9
~0.4 - 10µM
~20 µM
~100 µM
100± 9 µM
4.6 ± 0.3 nM
134.4 ±7.2 µM
[80]
[80]
[80]
[85]
[147]
[152]
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12 B. Strehlitz, et al.Thalidomide DNA T5-B
T5-1-B
T5-1a
113 µM
133 µM
1.05 ± 0.59 µM 
[89]
Dopamine RNA dopa2
dopa2/c.1
2.8 µM
1.6 µM
[61]
Analgetics Diclofenac DNA D10/DA24
D22
D16
D3
100.64± 40.5 nM
166.34± 57.9 nM
148.73 ±15.5 nM
42.7±15.9 nM
[94]
Substance class  Selection target  Chemical structure - o g i l O
nucleotide
Name of 
aptamer 
KD value Ref 
Ibuprofen (racematic
form)
DNA IBA2
IBA8
IBA12
IBA4
IBA17
IBA4
IBA17
3.0 µM (for racematic form)
5.2 µM (for racematic form)
3.2 µM (for racematic form)
1.5 µM (for (S)-isomer)
3.8 µM (for (S)-isomer)
2.4 µM (for racematic form)
6.8 µM (for racematic form)
[97]
Hormones Estradiol DNA 0.1 – 3 µM
0.13 µM
[102]
Somatropin DNA 218 nM [105]
Insulin ] 8 0 1 [ A N D
Vasopressin DNA D-Aptamer 
L-Aptamer
0.9 µM for D-vasopressin
1.2 µM for L-vasopressin
[116]
Table 1 (continued)
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Thalidomide (also known under the brand names Contergan®
in Germany and Kevadon® in Canada and the USA)
was introduced as a sedative drug in the late 1950s, but
was withdrawn from the market in 1960s due to its
strong teratogenic and neuropathogenic effects. Thalid-
omide exists in two enantiomeric forms, the (R)- and
(S)-isomers which cause the differences in its biological
activity. While the enantiomers can interconvert (race-
m i z e )i nv i v o[ 86], their pathogenic mechanisms are still
not understood. Recently, thalidomide has been considered
as a potential drug for various diseases such as autoimmune
diseases, AIDS, Hansen’s disease, and some cancers [87, 88].
S h o j ie ta l .[ 89] generated a modified DNA aptamer
that binds the (R)-isomer of a thalidomide derivate with
high enantioselectivity. The aptamer selection was
designed using the racematic thalidomide derivate, which
was conjugated with biotin and immobilized on a
streptavidin gel. A modified DNA library was applied
which contained cationic ammonium groups attached by a
hydrophobic hexamethylene linker at the thymidine
residues (T
HM). Fifteen rounds of selection were carried
out, and the five aptamers with the highest binding
affinities to thalidomide showed a high guanine content.
Tests with the best binding aptamer exhibited that the
modified group T
HM was indispensable for the binding to
thalidomide. An affinity constant of 113 μMw a s
determined for the selected aptamer T5-B (biotinylated)
by SPR. The SPR measurements were carried out with a
derivate of thalidomide which was conjugated with a PEG
derivative as a weight tag. Truncated versions of the best
binding aptamer T5 (T5-1, T5-2, and T5-3) were used to
determinethe thalidomide-binding site which was expectedto
form a stem-loop structure. The fragment T5-1 was suggested
as the binding site of the aptamer T5. The dissociation
constant for the aptamer fragment T5-1-B determined by SPR
measurements was 133 μM which is almost the same as that
of the parent aptamer, T5-B. Studies with fluorescence
titration revealed a high enantioselective binding behavior of
the truncated aptamer T5-1a which recognized the (R)-isomer
of thalidomide. The dissociation constant of T5-1a was
estimated by fluorescence titration and was found to be
1.05±0.59 μM.
DNA aptamers for analgetics
Diclofenac
Diclofenac (DCF) is a nonsteroidal anti-inflammatory drug
with analgetic, antiphlogistic, antipyretic, and antirheumatic
properties. It is widely used to treat pain and inflammatory
disorders including musculoskeletal complaints (arthritis,
rheumatoid arthritis, polymyositis, dental pain, etc.). Diclofe-
nac belongs to the most frequently detected pharmaceutically
active compounds in the water cycle [90] causing critical side
effects for humans and also harmful environmental impacts.
Published are, e.g., noxious effects on vultures [91, 92]a n d
on freshwater fish species [93].
Joengetal.[94] produced DCF-binding aptamers by using
the FluMag-SELEX process [72]. After nine selection
rounds including counterselection steps with the structure
analog 2-anilinophenylacetic acid (2APA) and 4-amino-3,5-
dichlorbenzoic acid, an enrichment of three major groups
based on sequence similarity could be shown. Secondary
structure analysis revealed typical stem-loop structures. The
best binders D10/DA24, D16, D22, and D3 exhibited
specificity to the selection target DCF. Aptamers D22 and
D16 possessed higher specificities to 2APA than for DCF.
2APA is a structural analog of DCF lacking two chlorine
Gonadoliberin RNA
RNA
Spiegelmer
DNA
DNA
Spiegelmer
A10
A10 truncated
A10 truncated
Spiegelmer
S42
S42 truncated
S42 truncated
Spiegelmer
92 ±12 nM for D-GnRH
263 nM for D-GnRH
190 nM for L-GnRH
55±7 nM for D-GnRH
45 nM for D-GnRH
45 nM for L-GnRH
[122]
Substance class Selection target Chemical structure - o g i l O
nucleotide
Name of 
aptamer 
KD value Ref 
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14 B. Strehlitz, et al.atoms. For one of the aptamers (D3), specificity to DCF and
no significant binding to 2APA could be shown. For all of
these aptamers, no binding activity was detectable to 4-
amino-3,5-dichlorobenzoic acid (chemically not related) and
to naked beads. The determined KD values for immobilized
diclofenac averaged between 42.7 and 166.34 nM and are
given in detail in Table 1.
Ibuprofen
Ibuprofen is another representative nonsteroidal anti-
inflammatory drug which offers analgetic, antiphlogistic,
antipyretic, and antirheumatic properties. It is prevalently
used for arthritis, primary dysmenorrhea, and fever. Due to
the chirality of ibuprofen, there are two enantiomers with
different physiological effects. The (S)-(+)-ibuprofen was
found to be the active form both in vitro and in vivo [95],
while (R)-(−)-ibuprofen seems to be teratogenic [96].
To generate an enantioselective DNA aptamer for ibupro-
fen, Kim et al. [97] carried out a FluMag-SELEX [72] process
with racematic ibuprofen. Ten rounds of in vitro selection
including counterselection steps with other nonsteroidal anti-
inflammatory drugs (fenoprofen, flubiprofen, naproxen) were
performed. After this procedure, five different sequences
(mostly G-rich) could be found. They could be divided into
two sequence groups depending on the found consensus
regions. The aptamers of the first group (IBA2, IBA8,
IBA12) showed binding affinity to the racemic mixture of
ibuprofen but were not able to bind pure (S)-ibuprofen. On
this account, the authors concluded that they are specific for
the (R)-isomer. The affinity constants for this sequence group
were determined by an affinity elution assay to be 3.0 μM
(IBA2), 5.2 μM (IBA8), and 3.2 μM (IBA12). The aptamers
of the second group (IBA4, IBA17) possessed binding
affinities to the (S)-isomer (KD=1.5 μM (IBA4) and 3.8 μM
(IBA17)) as well as to the racematic form (KD=2.4 μM
(IBA4) and 6.8 μM (IBA17)) of ibuprofen. Neither the first
sequence group nor the second showed any binding affinity to
the other tested nonsteroidal anti-inflammatory drugs feno-
profen, flubiprofen, and naproxen or to oxytetracycline.
DNA aptamers for hormones
Estradiol
Estradiol (also 17β-estradiol or E2) is one of the predominant
sex hormones belonging to the class of steroid hormones.
Derivatives of estradiol are the most common estrogen
ingredients in combined oral contraceptive pills. Estradiol
itself has been widely applied in animal fattening for its
anabolic effects [98]. It is well-known that endocrine-
disrupting chemicals, including estradiol, have harmful
effects on aquatic organisms (e.g. [99, 100]). Also humans
are affected by chronic exposure since these chemicals reach
the natural aquatic systems and the drinking water [101].
Kim et al. [102]o b t a i n e d1 7 β-estradiol-specific ssDNA
aptamers after seven cycles of selection and enzymatic
enrichment in a SELEX process. The aptamers were
analyzed concerning their affinity to estradiol. Based on the
equilibrium filtration method, affinity constants for the ten
obtained aptamers were determined to be in a range of 0.1 to
3 μM, with a KD=0.13 μM for the best binding oligonucle-
otide. Secondary structure analysis indicated a stem-loop
structure for this estradiol aptamer. The aptamer was used in
an electrochemical detection method by immobilizing the
aptamer on a gold electrode chip. In that way, the authors
could show that the aptamer had no cross-reactivity to small
organic chemicals with structural similarities to estradiol
(methoxynaphthalene, aminoanthraquinone).
Huy et al. [103] used this aptamer for a novel separation
and enrichment method of 17β-estradiol from aquatic
samples by application of aptamer-anchored microbeads.
To achieve this, the estradiol-specific aptamers were amino-
tagged and covalently attached to isothiocyanate modified
glass beads. The experiments revealed a specific binding and
enrichment of 17β-estradiol from spiked water samples. No
binding to the antibiotics chloramphenicol and 3-[[(4-
carboxyphenyl) methylene] amino]-2-oxazolidinone and a
weak cross-reactivity to the estrogen diethylstilbestrol was
detected. The results of this study demonstrate the ability of
aptamer-based affinity methods for the separation and
enrichment of chemicals from environmental water samples.
Somatropin
Somatropin is the recombinant produced human growth
hormone (rhGH). In contrast, the natural human growth
hormone(hGH)iscalledsomatotropin.Bothareanionic,non-
glycosylated four helix-bundle proteins. Somatropin has a
strong anabolic effect. Therefore, it is often misused by
athletes to enhance their performance. But it is also applied as
medication to treat hypopituitary dwarfism, injuries, bone
fractures, bleeding ulcers, and burns [104].
Calik et al. [105] selected aptamers for somatropin using
the so-called single-step ligand evolution by temperature
gradient method. The characteristic step of this method is
an elution of the target-bound oligonucleotides by a
temperature gradient. In this way, the authors assumed that
aptamers with higher specificity to the target are separated
fromthose aptamerswith lower specificity. Atfirst,a negative
selection step with extracellular proteins of Bacillus subtilis
was performed because the aim of the aptamer development
was to separate and purify rhGH (somatropin) during the
production process from B. subtilis fermentation broth. After
this pre-selective step, the obtained oligonucleotide pool was
incubated with somatropin microparticles. The somatropin-
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temperature gradient within a range of T=55 °C to 95 °C.
At a temperature of 85 °C, eight aptamer sequences with
high affinity to somatropin were eluted. The KD value of the
best binder was determined to be 218 nM by equilibrium
binding analysis. By utilization of this aptamer immobilized
on microparticles, the authors were able to separate and
purify rhGH (somatropin) from the B. subtilis fermentation
broth with a purity of 99.8%.
Bruno et al. [106] developed aptamers, which are able to
discriminate between somatropin (rhGH) and somatotropin
(hGH) and bind these hormones in different levels. The
aptamers were obtained after five rounds of a microbead-
based SELEX procedure with rhGH and hGH as targets.
Eight of the found aptamer sequences indicated the ability
to discriminate recombinant produced somatropin (rhGH)
from natural somatotropin (hGH). Sequence analyses
discovered GGGTG as the most common sequence seg-
ment. Specificity tests by enzyme-linked aptamer assay
were carried out to determine cross-reactivity to proteins or
peptides of human body fluids and others. Regrettably, the
best rhGH discriminatory aptamers exhibited a cross-
reactivity to human myoglobin and to BSA (but not to bone
collagen peptides and to an unrelated viral envelope peptide),
which makes them inappropriate for measurements of rhGH/
hGH in body fluids.
Insulin
The well-known peptide hormone insulin has central
functions in carbohydrate and fat metabolism in vertebrates.
Dysfunctions in insulin balance lead to Diabetes mellitus
and related metabolic disorders. Worldwide, millions of
patients with diabetes depend on external insulin for their
survival because the hormone is no longer produced
internally. For this widespread clinical use, biosynthetic
“human” insulin is manufactured recombinantly [107].
To select insulin-binding aptamers, Yoshida et al. [108]
applied an ssDNA library which was expected to form
various kinds of G-quartet structures. This approach was
chosen because an insulin-linked polymorphic region (ILPR)
in the human insulin gene promoter was found that can form
an intramolecular G-quartet structure [109, 110]. The in vitro
selection itself was carried out by aptamer blotting. In order
to do this, human insulin as the target was immobilized on a
modified polyethersulfone affinity membrane. By using this
method, the binding of the oligonucleotides to the target
protein could be visualized. After six rounds of selection,
three aptamer sequences were obtained. Investigations of the
binding ability to insulin in solution by fluorescence
polarization measurement exhibited that two of the aptamers
had a higher affinity to insulin than ILPR (which can be
called “natural insulin-binding aptamer”). Circular dichroism
spectrum measurements revealed the aptamer folding into a
G-quartet structure while binding to insulin. Complementary,
the authors developed an aptameric enzyme subunit (AES)
by connecting the selected insulin-binding aptamer with a
thrombin-inhibiting aptamer [111] for insulin detection.
Using this AES, it was possible to detect insulin by measuring
enzymatic activity of thrombin.
Vasopressin
Vasopressin(alsoarginine vasopressinorantidiuretic hormone)
is a potent endogenous peptide hormone that controls the
re-absorption of molecules in the tubules of the kidneys by
affecting the tissue’s permeability. It also increases peripheral
vascular resistance, which in turn increases arterial blood
pressure. It plays a key role in homeostasis and the regulation
of water, glucose, and salts in the blood. It acts as a
neurotransmitter in the brain to control the circadian rhythm,
thermoregulation, and adrenocorticotropic hormone release
[112–114]. The therapeutic use of vasopressin has become
increasingly important in intensive care, in the management
of cranial diabetes insipidus, bleeding abnormalities, esoph-
ageal variceal hemorrhage, asystolic cardiac arrest, and septic
shock [115].
Williams et al. [116]g e n e r a t e dam i r r o r - i m a g es s D N A
aptamer (L-DNA aptamer, similar to Spiegelmers [117]) to
achieve a nuclease-insensitive ligand. The aptamer selection
was carried out using the “selection–reflection” strategy.
First step of this procedure is the production of an enantiomer
(D-isomer) of the cyclic L-peptide arginine vasopressin. This
D-isomer of vasopressin was used as target for the selection
of natural D-ssDNA aptamers. The SELEX process was
realized by affinity chromatography [118]. The implemented
oligonucleotide library was produced with a raised G-content
because the authors expected G-quartet structures for
binding. Consequently, it was not surprising that the received
vasopressin aptamers exhibited a high G-content. The
binding region could be defined as a stem with an internal
loop of 20 nt that contains guanine nucleotides at conserved
positions. The truncated version of the D-ssDNA aptamer,
containingonlythe bindingregion, wasmirror-imaged intoits
L-form and tested for its ability to bind natural L-vasopressin.
This L-aptamer exhibited a more than 100-fold preference for
vasopressin compared to oxytocin which is the closest
known human analog (differing only in two peptide residues).
Dissociation constants were ascertained by equilibrium
dialysis experiments and were determined to be 0.9 μM
for D-aptamer/D-vasopressin and 1.2 μMf o rL-aptamer/L-
vasopressin. Stability and nuclease insensitivity of the D-/L-
aptamer was proofed with the following results: The L-
a p t a m e rs t a y e du n a f f e c t e dw i t h i n1 0d a y s ,a n dt h eD-aptamer
was degraded after 10 s by purified nucleases. Furthermore,
the L-aptamer was not degraded in human serum and only to
16 B. Strehlitz, et al.a small extent in calf serum. Additionally, the bioactivity of
the L-aptamer as a vasopressin antagonist was confirmed in
cell culture.
Gonadoliberin
Gonadoliberin is a peptide hormone (also gonadotropin-
releasing hormone I (GnRH) or gonadorelin) responsible for
the release of follicle-stimulating hormone and luteinizing
hormone [119]. Therapeutically, it is often used in cases of
fertility dysfunctions [120]. Gonadoliberin analogs are
applied to treat breast or prostate carcinoma, endometriosis,
and precocious puberty [121].
Levaetal.[122] assembled GnRH-specific RNA and DNA
Spiegelmers. Initially, a SELEX process to get natural D-RNA
and D-ssDNA ligands for mirror-imaged gonadoliberin (D-
GnRH) was implemented. In both cases, the selection for
RNA and DNA aptamers was carried out by affinity chroma-
tography using D-GnRH immobilized on thiol-modified
sepharose. After six rounds of the RNA-SELEX, only one
major binding sequence (named A10) was found which bound
D-GnRH with a KD value of 92±12 nM (determined by
equilibrium dialysis). Eight rounds of the DNA-SELEX led to
nine different sequences which were able to bind GnRH. A KD
value of 55±7 nM could be determined for the DNA aptamer
with the highest affinity (named S42). The selected RNA and
DNA variants showed no similarity to each other, neither
concerning their primary sequence nor their proposed secondary
structure. Truncations to ascertain the minimal binding domain
indicated that 48 nt of the RNA aptamer form a three-way helix
junction with four unpaired nucleotides at the branching point,
while the DNA aptamer (68 nt) forms a G-quadruplex structure
flankedbytwostems.Furthersubstitutionsanddeletionsledtoa
60-nt DNA aptamer which boundto D-GnRH with KD=45nM.
The affinity constant of the Spiegelmer to L-GnRH was the
same. Both constants were determined by equilibrium dialysis.
The affinity constants for the truncated RNA aptamer and its
Spiegelmer were determined by isothermal calorimetry. The
50-nt truncation of the RNA aptamer A10 showed KD=
263 nM to D-GnRH, whereas the Spiegelmer L-RNA bound to
L-GnRH with KD=190 nM. Truncation of the RNA aptamer to
a 50-mer decreased the binding affinity to half, whereas
truncation of the best binding DNA sequence to a 60-mer did
not alter the binding affinity [122].
Specificity tests were carried out by SPR real-time kinetic
measurements. Both Spiegelmers exposed high specificity for
gonadoliberin since the exchange of a single amino acid
resulted in a dramatic loss of binding affinity (shown for
chicken LHRH). The RNA Spiegelmer also recognized the
GnRH analog buserelin, albeit with reduced affinity, while
the DNA Spiegelmer showed nearly no binding to buserelin.
No binding activity could be detected to the completely
unrelated peptides vasopressin and oxytocin. Cell experi-
ments clearly demonstrated that both Spiegelmers were able
to inhibit the binding of GnRH to its cell surface receptor.
In contrast to the development of RNA aptamers, DNA
aptamers for pharmaceuticals are often selected for diagnostic
and analytical applications. DNA aptamers are therefore
widelyusedtoanalyze bodyfluids. However, theyare equally
valuable for the detection of pharmaceutical residues in food
or in the environment. Moreover, some research groups
develop protocols not to implement aptamers in measurement
and detection systems, but for application as affinity compo-
nents in enrichment and purification methods. In contrast to
DNA aptamers, the development of Spiegelmers is generally
focused on a therapeutic application.
Independent of both the designated application and the
selection method, it is remarkable that most DNA aptamers
developed for pharmaceuticals exhibit a high guanine
content. In several cases, G-quadruplex structures were
identified as the binding regions, and it is noteworthy that
also the “natural” aptamer for insulin (the insulin-linked
polymorphic region in the human insulin gene promoter)
forms an intramolecular G-quartet structure [109, 110].
Several studies indicate these structures to form highly
competent binding configurations, especially for small
bioactive molecules [123–125]. Considering the innumera-
ble possibilities for the potential formation of G-quadruplex
structures on the genomic level, these structures may occur
more often in living cells than currently anticipated. Besides
that, G-quadruplexes seem to be very convenient ligands for
small molecules with pharmaceutical properties.
Aptamer-based detection systems
In comparison to other biological recognition elements, such
as antibodies, aptamers are more stable to biodegradation and
less vulnerable to denaturation. Their target binding is
regenerative. Therefore, they are prime candidates for
biosensors and assays in a number of applications, such as
environmentalmonitoringandmedicaldiagnostics[126]. The
key challenge to their successful application is the transfor-
mation of the aptamer-binding events into physically
detectable signals. To meet the challenge, a number of
methods have been developed. Some aptamers bind their
target by a contemporaneous structure switch. Such biomo-
lecular switches enable transduction of the binding event into
a specific output signal in a single step and without the
addition of exogenous reagents and without the use of labels
[127]. They can be used also in connection with markers
(labels) fixed to the structure. These markers can be for
instance redox active or optically active. The binding
between the structure switching aptamer and its target
induces a change of steric configuration of the aptamer
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cation with electrochemically or optically active labels is
very easy because the chemical synthesis procedures used
for aptamer production provide a lot of standard methods for
chemical binding of reporter molecules or reactive groups.
Most of the aptamer-based detection systems are described
with one of the well-known aptamers for thrombin or cocaine
serving as model aptamers. Cocaine belongs to the psycho-
tropic pharmaceuticals, and therefore, these aptamer-based
sensors are included in this review.
Biosensors couple the biological recognition of the
analyte by a biological receptor (which may be an
aptamer—“aptasensor” [128]) with a chemical or physical
transducer. The characteristic feature of the biosensor is,
according to the International Union of Pure and Applied
Chemistry definition, the direct contact of the recognition
element and the transducer [129]. The aptamer-based
systems for the detection of pharmaceuticals reviewed in
this article include not only biosensors which fulfill this
definition but also optical assays with separated aptamer-
based detection and signal recognition, for instance in
colorimetric assays or test strips. The sections below give
detailed descriptions about the aptamer-based sensors and
assays, summarized at a glance in Table 2.
Electrochemical aptasensors
Electrochemical transducers offer some advantages in com-
parison to optical and other transducers such as ultrahigh
sensitivity and simplicity [130]. Electrochemical transducers
are the most frequently used in commercialized biosensors,
for instance for blood glucose testing. The small size of
Table 2 Examples of aptamer-based biosensors and assays for pharmaceutical detection
Target/
measurement of
DNA/RNA
aptamer
Ref of aptamer
description
Transducer/assay Limit of detection Linear range (μM) Ref of
sensor/assay
Oxytetracycline DNA [70] ec, chip system, labeled 0.005–0.1 [137]
Tetracycline DNA [69] ec, screen-printed electrode,
CV, SWV, label-free
10 nM 0.01–10 [139]
Neomycin RNA [35] ec, competitive impedimetric,
label-free
0.75–500 [140]
Tobramycin RNA [27] ec, competitive impedimetric,
label-free
ATA 0.7 μM ATA 1.4–70 [141]
FATA 0.4 μM FATA 0.8–34.9
Aminoglycoside RNA [27] ec, labeled 2–6[ 142]
Cocaine DNA [80] Optical, colorimetric, labeled 50–500 [126]
Cocaine DNA [80] Optical, FRET, labeled 10–4,000 in blood
serum
[80]
Cocaine DNA [80] Optical, colorimetric dipstick 10 μM[ 149]
Cocaine DNA [80] ec, microfluidic, labeled 10–100 in blood
serum
[85]
Cocaine DNA [80] Optical, FRET, labeled 10 μM1 0 –1,000 This publication
Cocaine DNA [79] Optical, FRET, labeled 10–1,250 [79]
Cocaine DNA [79] Optical, FRET, labeled 1 μM1 –1,000 [143]
Optical, excimer fluorescence,
labeled
100 μM 100–1,000
ec, LSV, labeled 10 μM1 0 –1,000
Cocaine DNA [80] ec, CV, labeled <10 μM[ 82]
Cocaine DNA [79] ec, pulse voltammetry, label-free 0.1 μM 0.1–38.3 [145]
Cocaine DNA [79] ec, chronocoulometric, label-free 70 nM 0.1–26.3 [130]
Cocaine DNA [80] Optical, colorimetric, labeled 50 nM 0.1–20 [153]
Cocaine DNA [80] Electrogenerated chemiluminescence,
labeled
1 nM 0.005–0.3 [146]
Cocaine DNA [80] Optical, fluorescence, rolling
circle amplification, labeled
0.48 nM 0.001–0.05 [154]
Cocaine DNA [82] Electrogenerated chemiluminescence,
labeled
10 pM [147]
Vasopressin L-DNA [116] Optical, SERS, label-free 5.2 μU/ml [155]
Dopamine RNA [61] Optical, colorimetric, ELAA,
labeled
1 pM 0.00005–0.1 [156]
17β-Estradiol DNA [102] ec, CV, SWV, label-free 0.00001–0.001 [102]
CV cyclic voltammetry, ec electrochemical, ELAA enzyme-linked aptamer-based assay, FRET fluorescence resonance energy transfer, LSV linear
sweep voltammetry, SERS surface-enhanced Raman spectroscopy, SWV square wave voltammetry
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unit as sensor or chip system and to integrate them with the
electronics of the device permit the construction of hand-held
devices or in-field/at-side devices. Aptamer-based biosensors
with electrochemical transduction [131–133] and also with
various amplification methods of the aptamer-based signal-
tracing are described [130].
Sassolasetal. havereviewedarticlesaboutelectrochemical
aptasensor development written in the years between 2004
and 2009 [134]. The article presents clearly drawn schemes
of the different configurations of labeled and non-labeled
detection and between signal-on and signal-off electrochem-
ical detection principles and describes advantages and
disadvantages of them.
Sadik et al. describe in their review dealing with
biomolecular recognition by use of electrochemical techni-
ques various electrochemical aptasensors that were developed
recently [135]. Electrochemical detection of the aptamer
reaction with the target is based on labels such as enzymes,
nanoparticles, quantum dots, or redox active molecules, or
on a binding-induced label-free detection. A reagentless,
electrochemical aptamer-based sensor (E-AB sensor) was
developed [82, 133, 136], which is a platform for aptamer-
based detection. One of the ends of the aptamer is immobi-
lized at the electrode surface. At the other end, a redox active
label is attached to the aptamer, which is able to undergo a
redox reaction with the electrode. In the case of binding of the
target molecule to the aptamer, its conformation is changed
and the distance between the redox active label and the
electrode surface is decreased, which in turn causes a change
in the electrochemical signal. Even though—regarding
pharmaceuticals—aptamers were developed for many sub-
stances and substance classes, only a few of them are in fact
used in electrochemical biosensors. In the sections below,
electrochemical aptasensors for antibiotics, psychotropics,
and hormones are described as they are found in the literature.
Antibiotics
An electrochemical aptamer-based chip system, consisting of
a gold working electrode chip with eight electrodes in parallel
and using the K3Fe(CN)6 redox mediator (comparable to the
system described in [102]) was used for oxytetracycline
detection. Kim et al. immobilized the thiol-modified oxytet-
racycline specific DNA aptamer no. 14 described in [70]o n
a gold interdigitated array [137]. The reference and counter
electrode used are not specified in their work. The redox
reaction between ferrocyanide and ferricyanide is measured
by cyclic voltammetry (CV) and square wave voltammetry
(SWV) before and after binding of oxytetracycline to the
immobilized aptamers. The dynamic range of the sensor lies
between 5 and 100 nM oxytetracycline. Structurally related
tetracycline derivatives such as doxycycline and tetracycline
were distinguished from oxytetracycline [137]. Sensor
regeneration was achieved by use of 2 M NaCl [137, 138].
Kim et al. [139] used a screen-printed gold electrode
with silver reference electrode and gold counter electrode
for the immobilization of the tetracycline binding DNA
aptamer T20, whose selection was described in [69]. The
aptamer was extended by a poly-T tail for flexibility and
spacing at the 5′-end and labeled with biotin to immobilize
it at the streptavidin-modified electrode. The same detection
principle as in the sensor example above was used: The
redox reaction of the redox mediator K3Fe(CN)6 was
measured by CV and SWV at the aptamer-modified
electrode before and after binding of the target. The
decrease of the current quantifies the target bound to the
aptamer. This label-free sensor showed a dynamic range for
tetracycline detection of 10 nM to 10 μM and a limit of
detection of 10 nM tetracycline. The aptamer used in this
aptasensor can weakly recognize other tetracyclines like
oxytetracycline and doxycycline [69], so the sensor has
lower specificity and can detect tetracycline and its
derivatives [139].
Faradaic impedance spectroscopy was used for neomycin
detection with a competitive RNA aptamer sensor [140]. The
neomycin B-specific RNA aptamer [35, 37] was stabilized
by 2′-O-methylation. The aptamer was bound to neomycin B
immobilized on a gold electrode. The assay procedure
consists of 5-min incubation of the electrode in the affinity
solution with varying concentrations of neomycin B and
subsequent transformation to the measuring solution, which
contains the redox probe [Fe(CN)6]
3−/4−. The impedance
spectrum at a bias potential of +0.225 V (Ag/AgCl/KClsat)
using a frequency range from 10 kHz to 100 mHz and an
alternating current amplitude of 5 mV is measured. The
increase of neomycin B in the affinity solution causes an
increasing aptamer displacement from the electrode which is
measured as an impedance change [140]. The linear range of
the label-free sensor is from 0.75 to 500 μMn e o m y c i nB .
The measurement is fast because the aptamer displacement
by neomycin B requires only 5 min. The electrode surface
can be regenerated. In concentrated neomycin solution, all
remaining aptamers are released. Further rebinding of the
aptamer results in a fresh aptamer-bound surface [140]. The
sensor was stored in neomycin solution. One week storage
and 20 measurement cycles are possible without significant
loss in sensitivity. The practical test was done in milk spiked
with neomycin. The sample pretreatment consisted in 1:5
dilution of the sample in affinity buffer and ultracentrifugation.
The linear range for the measurement in milk is between
25 μM and 2.5 mM neomycin B [140].
A comparable RNA aptamer-based displacement impedi-
metric sensor for tobramycin detection was described by
Gonzalez-Fernandezetal.[141]. The RNA aptamer developed
by Wang and Rando [27] was stabilized by 2′-O-methylation
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before and described in [140]. Two types of aptamer
methylation were tested, the fully modified aptamer (FATA)
is methylated at each base, in contrast to the partially modified
aptamer called ATA. The aim of this study was to detect
tobramycin in human serum. Both aptamers were tested in the
displacement assay by use of the impedimetric sensor which
worked as described before for neomycin detection [140]. The
changes in the electron transfer resistance that resulted from
biosensing events between the redox probe ([Fe(CN)6]
3−/4−)
and the modified electrode were measured as the impedance
spectra (at a bias potential of +0.225 V (Ag/AgCl/KClsat)
using a frequency range from 10 kHz to 100 mHz and an
alternating current amplitude of 5 mV). In this way, the
analyte tobramycin could be detected in solution by the
displacement of aptamers bound to the tobramycin-modified
sensor surface. The ATA aptamer showed a limit of detection
of 0.7 μM and a linear range of 1.4 to 70 μM for tobramycin.
Regeneration of the sensor surface was done by incubation in
concentrated tobramycin solution for 1 h, removing all of the
aptamer molecules from the electrode surface. Subsequently,
the tobramycin-modified surface can be re-saturated by the
aptamer and re-used for measurement. The sensor could be
used for 1 week when stored between measurements in the
regeneration solution (conc. tobramycin solution) at 4 °C. The
selectivity was tested with respect to the aminoglycosides
kanamycin, neomycin B, paromomycin, and streptomycin.
The tobramycin–ATA aptamer sensor was able to discriminate
between tobramycin and kanamycin, paromomycin, and
streptomycin. However, neomycin B could be detected by
the sensor producing signals nearly the same as tobramycin.
By use of the fully methylated aptamer (FATA), a limit of
detection of 0.4 μM and a linear range of 0.8 to 34.9 μM
were found, which were in good agreement with the results of
ATA aptamer, suggesting similar affinities for both aptamers
for its target tobramycin. The measurement of tobramycin in
human serum was possible in the therapeutic concentration
range [141].
An RNA aptamer-based E-AB sensor for aminoglycoside
antibiotics detection is able to detect tobramycin, kanamycin,
and gentamicin. This aptamer does not discriminate between
these three aminoglycosides binding all three with similar
affinities. This sensor was developed for point-of-care
diagnostics. It allows measurement of aminoglycoside con-
centrations over the therapeutically relevant low micromolar
range (2 to 6 μM). Methylene blue (MB) is used as the redox
tag at the 3′-end of the RNA aptamer. The binding of the
aminoglycosides to the electrode-bound aptamer causes a
decrease in Faradaic current from the attached redox tag.
Nucleases in serum samples are removed by ultrafiltration,
whichis possible for thedetection of the small aminoglycoside
molecules. The measurement process with sample pretreat-
ment is complete in less than 30 min [142].
Pharmaceuticals with psychotropic effects
A rapid electrochemical aptamer biosensor for cocaine
detection is based on the target-induced conformational
change of the aptamer [82]. Baker et al. used the cocaine
DNA aptamer F7.9D described by Stojanovic et al. [80]
and coupled a MB redox tag to it. These modified aptamers
were immobilized on a gold electrode by self-assembly via
an alkanethiol group. The methylene blue reduction peak of
the AC voltammogram increases with increasing cocaine
concentration. The authors assume that in the absence of
the target cocaine the aptamer remains partially unfolded,
but with addition of cocaine the aptamer folds into a typical
three-way junction structure causing an alteration of the
MB reduction peak. The sensor is “signal on,” in contrast to
the decreasing signal for the thrombin sensor described one
year before [131]. The thrombin sensor construction was
the same, whereas the thrombin aptamer shows a different
folding reaction on target binding. The thrombin DNA
aptamer folds into a G-quadruplex structure in the presence
of the target [131] in contrast to the cocaine aptamer which
folds into a three-way junction structure [82]. In the first
case the signal changes are caused by the MB tag, which
veers away from the sensor surface, and in the second case
the MB tag approaches the electrode surface. The detection
limit of the cocaine biosensor is given to be below 10 μM.
The sensor enables an easy detection of 500 μM cocaine in
fetal calf serum or human saliva [82].
A microfluidic electrochemical aptamer-based sensor
(MECAS) was developed [85] based on the same cocaine
aptamer F7.9D [80] which was labeled with MB for
electrochemical sensing of the target binding as described
directly before [82]. The MECAS chip consists of three gold
electrodes at which the thiolated aptamer is immobilized, a
platinum counter electrode and a platinum reference electrode
within a 750-nl detection chamber. By use of this micro-
fabricated electrochemical aptamer biosensor, the continuous,
real-time detection of cocaine in undiluted, unmodified blood
serum in the physiological range was shown [85]; 10 to
100 μM cocaine in blood serum was measured, and the
dissociation constant for the aptamer binding was determined
to be 100±9 μM, which is identical to that for the aptamer in
solution [80, 85].
Another MECAS is reported by Du et al. [130]f o r
simultaneous detection of ATP and cocaine as model targets.
Here we will only review the cocaine detection by this
method, because ATP is not a relevant pharmaceutical
residue which has to be detected by environmental monitor-
ing. Two cocaine aptamer fragments derived from [79]w e r e
used. This MECAS chip consists of four groups of three-
electrode systems. Each group of three-electrode systems
consisted of two gold working electrodes, which shared one
gold counter electrode and one Ag reference electrode.
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cover the glass chip. One subunit of the cocaine aptamer is
immobilized on the gold surface of a working electrode
desired for cocaine detection. The second subunit of the
aptamer is immobilized on gold nanoparticles (Au-NP).
These marked Au-NP are pumped together with the cocaine
solution into the chip system for detection. In case of cocaine
binding, an agglomerate is formed at the electrode surface
consisting of the cocaine molecule bound between the two
subunits of the cocaine aptamer together with the Au-NP
load bearing some more aptamer subunits. Subsequently, the
electrochemical probe [Ru(NH3)6]
3+ (RuHex) binds to the
surface-confined DNA via electrostatic interaction and is
measured by chronocoulometry. The Au-NP are used to
produce an amplified electrochemical signal and improve the
sensitivity ofthe sensor. The detection limit for cocaine ofthis
sensor is 70 nM and the linear range is 0.1 to 26.3 μM[ 130].
Freeman et al. [143] showed three different possibilities
to use the self-assembling cocaine aptamer subunits [79].
The electrochemical cocaine detection by use of these
subunits and a methylene blue label is described here; the
optical methods based on FRET and excimer fluorescence
are described in the following chapter “Optical test systems:
biosensors and assays.” The electrochemical cocaine
aptamer sensor consists of the thiol-modified aptamer
subunit C2-D from [79] immobilized on a gold electrode
and the methylene blue (MB
+)—modified subunit F-C1
[79]. Linear sweep voltammograms were measured by use
of a graphite counter electrode and a saturated calomel
reference electrode (SCE). In the absence of cocaine, a low
intensity voltammetric response is observed, which might
be attributed to a minute nonspecific binding of the MB
+ to
the electrode surface [143]. In the presence of cocaine, the
synergistically stabilized supramolecular complex, consisting
of cocaine and both aptamer subunits, is formed on the
electrode surface. The confinement of the redox label
(methylene blue) at the electrode surface enables an electro-
chemical readout of the formation of the cocaine aptamer
complex correlating to the cocaine concentration [143]. The
detection limit of this sensor equates to 10 μM, the linear
measuring range is 10 μM to 1 mM. Other studies have
reported the electrochemical detection of analytes by a redox-
labeled aptamer, which is immobilized on the electrode. After
addition of the analyte (target), the aptamer-target binding
causes structural alignment of the redox label in respect to the
electrode [82, 143, 144]. In the absence of the analyte this
electrode arrangement of the redox label causes a large
electrical background response whereas the structural rear-
rangement caused by the presence of analyte only leads to
small voltammetric changes [143].
Alabel-freeelectrochemicalaptasensorwasconstructed by
use of a layer-by-layer self-assembled multilayer with
ferrocene-appended poly(ethyleneimine) (Fc-PEI) on an
indium tin oxide (ITO) array electrode [145]. Ferrocene is
the redox mediator which is incorporated in the electrode
surface. Fc-PEI and gold nanoparticles (Au-NP) are assem-
bled layer by layer on the electrode surface. The cocaine
aptamer fragments from [79] are used. One cocaine aptamer
fragment, which is labeled with a SH-group, is coupled to
the outermost Au-NP layer. The other cocaine aptamer
fragment is able to hybridize partly with the first aptamer
fragment and binds to the target cocaine. This binding causes
a decreasing in the differential pulse voltammetry signal of
Fc-PEI. The big advantage of this sensor construction is the
incorporation of the electrode mediator in the electrode
surface. The sensor has a linear range of 0.1 μMt o3 8 . 3μM
and a detection limit of 0.1 μM. It was applied in spiked real
samples of human plasma, human serum, human saliva, and
human urine (25% biological fluids). The recovery of
3.8 μM cocaine in the 25% biological fluids was between
101.4 and 105.8% and 96.1 and 102.7%, respectively, which
means that the measurement of cocaine in biological fluids is
possible by use of this aptasensor.
Electrogenerated chemiluminescence (ECL) technique
was used with the cocaine aptamer F7.9D from [80] labeled
at its 3′terminuswiththerutheniumcomplex Ru(bpy)2(dcbpy)
NHS [146]. Thisaptamerisimmobilizedontoagoldelectrode
surface via thiol-Au interactions. As in some other applica-
tions, the cocaine aptamer [80] remains partially unfolded in
the absence of target, resulting in a small ECL signal due to
the distance between electrode surface and tag. In the
presence of target, the aptamer folds in the three-way
junction structure and thus a strong ECL signal is measured
due to the tag moving closer to the electrode surface. The
ECL signal is generated by polarization of the electrode to
+0.8 V in 0.1 M phosphate-buffered saline (PBS) containing
0.1 M tripropylamine (TPA). Sensor characteristics are the
detection limit of 1 nM cocaine, a linear measuring range of
5n Mt o0 . 3μM cocaine, and no cross-reactivity to heroin
and caffeine. The sensor is regenerable in 2 ml of 0.10 M
PBS (pH 7.40) for four minutes with two times and by
extensively washing with water according to [82]. Long-term
storage stability was proved by storage at 4 °C over 10 days,
with no significant change of the measuring signal for 50 nM
cocaine [146].
In a subsequent work an electrogenerated chemilumi-
nescence (ECL) sensor for cocaine detection uses the
cocaine aptamer labeled with a ruthenium derivative
(cocaine aptamer-Ru1) [147]. The 30-mer cocaine aptamer
from Baker et al. [82], which is in fact based on the cocaine
aptamer described by Stojanovic et al. [80], was modified
with spacers and the Ru1 complex (which is not specified
in the article). The cocaine aptamer-Ru1 is covalently
coupled to the surface of a paraffin-impregnated graphite
electrode that had been covalently modified with a
monolayer of 4-aminobenzene sulfonic acid using electro-
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performed with a potential-step excitation from an initial
potentialof0Vtoaconstantpotential+1.35Vvs.Ag/AgClin
a0 . 1MT P A —0.1 M PBS (pH 7.4) solution. As described
above, the cocaine aptamer folds in the well-known three-
way junction structure with cocaine binding, which brings
the Ru 1 modification nearer to the electrode. Quantification
of cocaine is based on the ECL peak intensity change. The
ECL emissions were detected with a photomultiplier tube.
With this cocaine aptamer-Ru1-based sensor, the binding
constant between cocaine and its aptamer was estimated to
be 4.6±0.3 nM [147]. The selectivity was tested with
caffeine and heroin, which did not interfere with cocaine.
The sensor was reusable (RSD=2.8%, n=7) and had a good
long-term storage stability at 4 °C (recovery of 96.8% and
92.3% after 21 and 30 days). This cocaine sensor has a
detection limit of 10 pM for cocaine, which is 2 orders of
magnitude lower than that of the above mentioned ECL
cocaine aptamer sensor with self-assembled aptamer-
Ru(bpy)3
2+ [146].
Hormones
An electrochemical aptasensor for 17β-estradiol consists of
the DNA aptamer-modified gold working electrode chip
(eight electrodes in parallel) using the biotin-streptavidin
coupling system, a platinum counter electrode, and an Ag/
AgCl reference electrode [102]. K3Fe(CN)6 is used in
solution as the electron mediator. CVand SWVare used for
the measurement of the redox reaction between ferrocya-
nide and ferricyanide. Binding of 17β-estradiol molecules
to the aptamers causes measurable changes in electrical
current. The linear range of the biosensor was 0.01 to 1 nM
17β-estradiol [102].
Optical test systems: biosensors and assays
Optical signals such as fluorescence and color are preferred
for affinity-based recognition in biosensors because they
are easily detectable with high sensitivity and minimal
instrumentation. Fluorescence-based detection found grow-
ing interest for real-time in-field measurement because of
recent advances in miniaturization of the fluorescence
excitation sources and emission detectors [16].
The signals of colorimetric sensors and assays can be
detected by the naked eye under some circumstances. By
this way, the need of instruments is eliminated which makes
the application easier for unskilled personnel and household
application [16].
Au-NP possess a number of useful properties, such as
very high extinction coefficients and distance dependent
color display (aggregated particles are blue or purple,
dispersed particles are red). Highly sensible and simple
tests like colorimetric assays or lateral flow-based test strips
can be constructed [16]. For competitive aptamer-based Au-
NP colorimetric sensors, the affinity ratio of the aptamers to
both unmodified Au-NP and target (KD(AuNP)/KD(Target))
was detected as a tool to design more sensitive small
molecule detection systems [148]. The lateral flow tech-
nology is used in some common applied antibody tests, as
the well-known commercially available pregnancy test kit.
The user friendliness of this format allows its application by
users without laboratory background. No precise transfor-
mation of solutions is necessary. The result is shown more
or less as a “yes/no” answer, but with clear discrimination
because of the negative controls incorporated. Such a lateral
flow system is described for aptamer nanoparticle-based
disaggregation reaction for cocaine detection [149].
Pharmaceuticals with psychotropic effects
The frequently used cocaine aptamer was introduced by
Stojanovic and coworkers in the years 2000 to 2002 with
three assays. At first, an aptamer self-assembly with
fluorescence quenching was described [79]. In this case,
the aptamer sequence was divided in two subunits: One
(named C2-D) is labeled with a 3′-dabcyl quencher and the
other (named F-C1) with 5′-6-carboxy-fluorescein fluoro-
phore [79]. The two subunits behaved as a self-assembling
fluorescent cocaine assay, which was able to report cocaine
concentrations in the range of 10 to 1250 μM in the
respective selection buffer solution [79]. The fluorescein
emission at 518 nm (λex=472 nm) was quenched to 65% of
the initial value with 1 mM cocaine. The assay showed
selectivity for cocaine over its metabolites benzoyl-ecgonin
and ecgonine methyl ester [79].
The second assay is based on the cocaine aptamer MNS-
4.1 [80]. MNS-4.1 consists of three stems S1, S2, S3 with
the assumed cocaine binding pocket located in the
lipophilic cavity in the center of the three-way junction
structure. They engineered an instability in one of the stems
of this aptamer which results in a structure that is dependent
on the stabilization provided by ligand binding to form the
three-way junction. Double end labeling of the opened stem
with 5′-fluorescein fluorophore and 3′-dabcyl as quencher
resulted in the F7.9D cocaine aptamer. This assay operates
for cocaine detection in serum in the micromolar range
(10 μM to 4 mM) and is characterized by a dissociation
constant of ∼100 μM[ 80]. In their third article, Stojanovic
and Landry [81] introduced a colorimetric dye displacement
assay. The cocaine aptamer MNS-4.1 [80] is incubated with
the cyanine dye diethylthiatricarbocyanine iodide, which
complexed to the aptamer in the sequence region of the
cocaine binding pocket. In the presence of cocaine, the dye
is replaced and cocaine binds to the aptamer. A change in
the absorption spectra of the dye can be detected depending
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sensitivity and selectivity of this colorimetric assay was
slightly better than that of the corresponding fluorescent
assay for cocaine [80, 81].
An assay based on the same aptamer subunits from [79]
was described which makes use of the quantum dots (QDs)
stimulated fluorescence resonance energy transfer reaction
in connection with aptamer-target binding and formation of
the stable cocaine–aptamer supramolecular structure [143].
CdSe/ZnS quantum dots were bound to the C2-D subunit of
the cocaine aptamer [79], and the Atto 590 dye was bound
to the F-C1 subunit from [79]. In the presence of cocaine,
the supramolecular cocaine–aptamer complex is synergisti-
cally stabilized by the base pairing of the tethered chains,
giving rise to the stable cocaine–aptamer supramolecular
structure. This results in the FRET process between the
QDs and the dye acceptor [143]. Luminescence spectra
were measured and the assay was characterized by a
detection limit of 1 μM and a linear measuring range up
to 1 mM cocaine [143]. In a further variation, the authors
use the formation of the pyrene excimer structure and its
characteristic fluorescence. Pyrene molecules are bound to
both aptamer subunits. In the absence of cocaine, the
fluorescence spectra are characterized by pyrene monomer
emission peaks. Upon the addition of cocaine, the fluores-
cence of pyrene monomers decreases, and the characteristic
fluorescence of the pyrene excimer at λ=480 nm is
observed. This assay showed a detection limit of 100 μM
and a linear measuring range up to 1 mM cocaine [143].
For fast colorimetric sensing, a general sensor design
based on aptamers and gold nanoparticles was described
[126]. The big advantage of simple colorimetric assays is
that they render analytical instruments unnecessary what
makes the test easier and cheaper in most cases. The optical
properties of metallic nanoparticles are characterized by
their distance dependence and high extinction coefficients.
Thus, they were used for DNA-related colorimetric assays
based on Watson–Crick base pairing [150]. Aptamers may
be also used in combination with Au nanoparticles [151]. A
more general method for sensor design was described for
cocaine detection based on the reported cocaine aptamer
[80], with slight modifications [126]. The sensing principle
is based on the disassembly of Au nanoparticle aggregates
by binding of cocaine to the aptamer. The nanoparticle
aggregates containing three components [126]: a linker
DNA, representing the aptamer with a sequence extension
at the 5′-end and two thiol-modified oligonucleotides,
which are coupled to separate Au nanoparticles and are
both complementary to the 5′-region of the linker DNA. So
the linker connects the two thiol-modified sequences and
aggregates the two types of Au nanoparticles. In solution,
these aggregates show a faint purple color. When cocaine is
added, the aptamer changes its configuration with binding
to cocaine. The linking between the two types of nano-
particles opens up and the nanoparticles dissociate away
from each other, which causes a color change from purple
to red. This color change is concentration dependent.
Cocaine concentrations in the range between 50 and
500 μM were detected by use of this assay [126]. The
detection of cocaine in the environment (e.g., in river water)
by aptamer biosensors was not described until now.
An aptamer-based cocaine assay was developed in our
group with the aim for application in environmental
analytics. In this case, the DNA cocaine aptamer [79–81]
was modified with markers for FRET-based detection of the
binding reaction by intermolecular aptamer beacon forma-
tion. The modifications of the aptamer sequence were done
in the style of Liu et al. [126] whereas an additional
fluorescence marker was added at the 5′-end. The aptamer
works in this assay in connection with a second comple-
mentary oligonucleotide which bears a DABCYL quencher
at the 3′-end (see Table 3). Figure 1 shows the function of
this aptamer-based cocaine assay. The measuring solution
contains two DNA molecules—the aptamer and the
quencher oligomer. In the absence of cocaine, the aptamer
has a partial unfolded structure, and the quencher oligomer
is able to hybridize to the aptamer. Fluorophore and
quencher come into close proximity. Energy transfer from
the excited fluorophore to the quencher molecule takes
place and causes fluorescence deletion. The fluorescence in
the measuring solution reaches a minimum. In the presence
of cocaine, the aptamer folds in the typical three-way
junction structure and a stable aptamer-binding complex is
formed. The quencher oligomer is displaced from the aptamer
Table 3 Sequences of the cocaine aptamer (original [79–81] and modified [152]) and quencher oligonucleotide [152] used for a cocaine assay
with FRET-based detection
Anti-cocaine aptamer (original [79–81]) 5′-GGGAGACAAGGATAAATCCTTCAATGAAGTGGGTCGACA-3′ 39 nt
Modified anti-cocaine aptamer 5′-Fl–ATCTCGGGAGACAAGGATAAATCCTTCAATGAAGTGGGTCTCCC-3′ 44 nt
+
Complementary quencher oligo 5′-GTCTCCCGAGAT-D-3′ 12 nt
The functionality of the assay is depicted in Fig. 1. Letters in bold are added nucleotides, letters in italic are replaced nucleotides, and underlined
are complementary sequence parts of the aptamer
Fl Fluorescein marker, D Dabcyl marker
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and quencher are now far away from each other. The
fluorescence intensity increases in dependence of the cocaine
concentration in the measuring solution. The functionality of
this assay was shown in binding experiments with cocaine
concentrations in the range of 0 to 5000 μM cocaine (Fig. 2).
The detection limit for cocaine was 10 μM, and the linear
range was 10 μM to 1 mM cocaine. Non-linear regression
analysis of the binding results was used for calculation of the
KD value which was determined to be 134.4±7.2 μM
(Fig. 2) for the aptamer in this assay [152].
Another colorimetric assay for cocaine is also readable by
the naked eye [153]. Two fragments of the cocaine aptamer
[80] are used. One is thiolated and covalently bound to
amine-functionalized magnetic nanoparticles (MNP). The
other fragment is labeled with a G-quadruplex DNAzyme
which can bind hemin and possesses peroxidase-like activity.
This DNAzyme can catalyze the H2O2-mediated oxidation of
3,3,5,5-tetramethylbenzidine sulfate (TMB). The same reac-
tion catalyzed by horseradish peroxidase (HRP) is often used
in colorimetric assays, for instance ELISA tests, because of
Fig. 1 Functionality of a
FRET-based cocaine assay by
use of the modified cocaine
aptamer and a quencher
oligonucleotide [152]. In the
absence of cocaine, the quencher
oligomer is able to hybridize to
the partially unfolded aptamer.
Fluorophore and quencher come
into close proximity and fluores-
cenceisdeleted.The fluorescence
in the measuring solution reaches
a minimum. In the presence of
cocaine, the aptamer folds in the
typical three-way junction
forming a stable aptamer-binding
complex. The quencher oligomer
is displaced from the aptamer
and released into the surrounding
solution. Fluorophore and
quencher are now far away from
each other. The fluorescence
intensity increases in dependence
of the cocaine concentration
in the measuring solution
Fig. 2 Measuring curve for cocaine detection by measurement of
fluorescence change in the aptamer-based cocaine assay (Fig. 1), c
[cocaine]=0–5m M[ 152]. The saturation curve was used for the
determination of KD=134.4±7.2 μM by non-linear regression analysis
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beads bearing one aptamer fragment, the other aptamer
fragment conjugated with the DNAzyme, and cocaine come
into contact in the measuring solution, cocaine binds to the
aptamer strands which fold into the three-way junction
structure on the surface of MNPs. The MNPs could be
separated from the excess of aptamer fragment-DNAzyme
complexes in solution by use of an external magnet.
Afterwards, hemin is added to the MNPs solution which
causes formation of the DNAzyme, which effectively
catalyzes the H2O2–mediated oxidation of TMB, giving rise
to a change in solution color. In the absence of cocaine, the
DNAzyme-conjugated aptamer fragment does not bind to the
MNP; thus, no background signal caused by this effect can
be found [153]. The color change of TMB as the measuring
signal was detected by the naked eye or by measuring the
absorption after terminating the TMB-H2O2 reaction by
addition of 1 M H2SO4. The assay has a linear range from
100 nM to 20 μM cocaine and a detection limit of 50 nM.
Selectivity was checked with methadone, ecgonine, and
pethidine which did not show an observable color change
compared to the background [153]. The assay was tested for
application in human plasma, serum, and urine. It provides a
simple experimental process, low background signal, and
good selectivity. Its detection limit (50 nM) is lower than that
of most colorimetric cocaine aptamer sensors or tests.
A “dipstick” test based on the same Au-NP—cocaine
aptamer [79–81]—linker—based assembly [126]w a s
described in [149]. Additionally, some nanoparticles were
modified with biotin for capturing using streptavidin. The
dipstick consisted of four pads: the wicking pad which is
dipped in the solution to be tested. The following conjuga-
tion pad is loaded with the Au nanoparticle–cocaine aptamer
aggregates which are of purple color. Test solution without
cocaine causes no disaggregation, and the aggregates do not
change their color and are not able to leave the conjugation
pad. Cocaine in the test solution causes disaggregation, and
the smaller scattered nanoparticles with aptamer-bound
cocaine are able to diffuse into the membrane pad. This
membrane is loaded with a stripe of streptavidin. The biotin-
marked nanoparticles are captured within this stripe giving a
red color because of their disaggregated state. The following
absorption pad collects all the remaining nanoparticles,
which are not captured by streptavidin, resulting in a slightly
red color. The detection limit for cocaine in buffer solution
w a sd e t e r m i n e dt ob e1 0μM. Thislateralflowassaywasalso
used for determination of cocaine in untreated human blood
serum. In this case, 10 μl of the serum sample was added
directly to the conjugation pad to rehydrate and react with the
nanoparticle aggregates. After 20 s, the wicking pad was
dipped into running buffer solution. The sensitivity in serum
was 20 times lower compared to that in buffer solution [149].
This lateral flow method should be a general approach
adaptable to other aptamers, as far as the target binding causes
a structure switch of the aptamer so that the nanoparticle
disaggregation can take place as described in [126].
A sensitive fluorescence-based method for quantitative
cocaine detection is based on an aptamer and rolling circle
amplification [154]. A cocaine binding aptamer which is in
its core region very similar to that described in [80] was
used. The aptamer was immobilized at Au-NP which were
bound to magnetic beads. A short DNA strand with
structure compatibility to a part of the aptamer sequence
was hybridized to the aptamer. In the presence of cocaine,
the short DNA strand was displaced from aptamer owing to
the cocaine aptamer binding. Next, the short DNA strand
was separated by magnetic beads and used to originate
rolling circle amplification as primer. The end products of
rolling circle amplification were detected by fluorescence
signal generation upon molecular beacons hybridizing with
the end products of rolling circle amplification. Cocaine was
detected in the range of 0.5 nM to 1.0 μMb yf l u o r e s c e n c e
measurement, with a detection limit of 0.48 nM cocaine and a
linear range of the assay from 1 to 50 nM [154]. Compared to
other aptamer-based assays and sensors for cocaine detec-
tion, this method possesses a very good sensitivity. However,
its practical use is limited because its mode of operation is
more complicated.
Hormones
An optofluidic surface-enhanced Raman spectroscopy
(SERS) device for on chip detection of vasopressin based on
an L-DNA aptamer developed by Williams et al. [116]w a s
described [155]. Vasopressin was fluorescein isothiocyanate
(FITC)-labeled, and the aptamer was incorporated in a
metallic multilayer nanotube SERS active substrate. SERS
signals from the FITC-labeled vasopressin which was bound
to the incorporated aptamers were measured. The detection
limit was 5.2 μU/ml vasopressin in PBS buffer solution.
A competitive ELAA for dopamine detection in serum
was developed by use of the RNA aptamer for dopamine
[61, 156]. The aptamer was 3′-biotin-labeled. The ELAA
consists of the immobilization of the biotin-labeled aptamer
in the wells of a neutravidin-coated microtiter plate.
Dopamine is added to the wells, and the plate is incubated
at 4 °C for 1 h while shaking. Afterward, dopamine–HRP
conjugate in assay buffer is added and incubated at 4 °C for
15 min at room temperature. Unbound dopamine–HRP
conjugate is removed by washing. TMB in substrate buffer
is added to each well and incubated for 10 min at room
temperature. The color development is stopped by 2 M
H2SO4, and absorbance is measured at 450 nm [156]. The
assay conditions for the competitive ELAA method were
optimized for dopamine detection in serum. The test is
characterized by a limit of detection of 1 pM and a dynamic
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cross-reactivity to norepinephrine (3.68%), whereas 3-
methoxytyramine, epinephrine, homovanillic acid, and 3,4-
dihydroxyphenylaceticacidshowedverylittlecross-reactivity
(<1%) [156]. In comparison to an ELISA method that uses
antibodies, the ELAA is more selective and sensitive and
shows a better linear range. It should be mentioned that
Walsh and DeRosa demonstrated that the DNA homolog of
the RNA aptamer which was used in this ELAA assay is
able to bind dopamine with improved affinity and similar
specificity [157], but was not tested in the ELAA assay
until now.
Conclusions
The astonishing broad range of pharmaceuticals for which
aptamers were developed includes mainly antibiotics (RNA
and DNA aptamers), psychotropics (RNA and DNA
aptamers), analgetics (DNA aptamers), and hormones
(DNA aptamers). The aim of RNA aptamer development
for pharmaceuticals was often to elucidate the mechanism of
action of a specific drug, whereas DNA aptamer development
was dedicated to detection of pharmaceuticals in clinical
diagnostics.
Biosensors and assays based on aptamers were developed
mostly using optical and electrochemical detection of the
binding signal between aptamer and target. For the detection
of antibiotics, mainly electrochemical detection was de-
scribed, whereas the cocaine aptamer is used in a big variety
of electrochemical and optical sensors and assays. The
structure of the cocaine aptamer with its unique sequence
forming a three-way junction and the corresponding structure
switch on target binding make it particularly suitable as a
model aptamer for the development of sensors and assays.
Particularly noticeable for the cocaine aptamer-based systems
is the generally higher sensitivity of electrogenerated chemi-
luminescence over electrochemical sensors and over other
optical assays.
Aptamer-based sensors and assays for the detection of
pharmaceuticals were, until now, developed generally either
as model systems or aiming at the application in clinical
diagnostics for the detection of drugs in human blood, serum,
or urine. The use of aptamers for environmental application,
especially for the detection of pharmaceutical residues in
surface and ground waters, is not yet in the focus of the
development of biosensors and assays. Only in a few articles
the application of pharmaceutical-specific aptamersasaffinity
tags for enrichment and purification is mentioned.
However, the health risk of pharmaceuticals in the
environment, which are found mostly in very small concen-
trations but with permanent exposure to humans and animals,
isnotyetadequatelyexplored.Consolidatedknowledgeabout
emission, distribution, degradation, formation of metabolites,
and adverse environmental effects is needed. The develop-
ment of alternative measuring systems for online and in-field
pharmaceuticals detection is necessary. Aptamer-based sen-
sors and assays could be an alternative to the conventional
methods of chemical analysis.
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